As a great deal of recent public discourse makes clear, black Americans have been disproportionately impacted by the fallout from the coronavirus pandemic. Though hampered by limited and fragmented data, recent public health reports suggest that in eight states, blacks are at least three times more likely to be infected by coronavirus than their white counterparts, and nationally, blacks are twice as likely to die from such infections. County-level and city-level data have typically suggested similarly troubling trends. These realities largely mirror patterns of racial disparity that exist on a wide range of adverse social indicators.

As someone who studies gun violence, the recent discourse on coronavirus disparities has called to my mind long-standing narratives around gun violence and black men. While typically well intended, these disparity discourses share a number of problems that have often done more to obscure than to advance our understanding of these issues, as well as how we might effectively confront them. Such problems include: (1) the tendency to treat race as a biological category and to presume that racial identity is a discrete risk factor for coronavirus or gun violence, (2) the promotion of public health interpretations that focus on behavioral norms and lend themselves to austerity-minded interventions, and (3) the treatment of racial disparities as distinct from broader patterns of structural inequality. At the intersection of these discourses, moreover, epidemiological metaphors of racism and gun violence as diseases akin to coronavirus are often invoked in lieu of more nuanced and historically grounded analyses of these issues.

In the end, these accounts are largely devoid of class analysis and have little to offer in terms of meaningfully tackling these issues. We need an alternative lens for understanding and addressing the common roots of these issues.

In the early weeks of the emerging coronavirus pandemic in the United States, a rumor that black people were somehow immune to the virus was going viral on social media and beyond. Atlanta rapper Waka Flocka, for example, asserted in a radio interview in early March that minorities cant catch coronavirus. Name one. It doesnt touch them soul food folks. While the very public March 11 diagnosis of NBA player Rudy Gobert, a Frenchman whose father is of Afro-Caribbean descent, and the subsequent diagnoses of other high-profile black celebrities, put a swift end to this ridiculous rumor, its racialist premise of biological determinism regarding the coronavirus has unfortunately persisted including in some perhaps surprising corners.

Citing early data on racial disparities in pandemic-related hospital admissions, for example, the Centers for Disease Control and Prevention (CDC) identified race as a potentially discrete risk factor for infection, although they cautioned that its potential impact as such need[s] to be confirmed with additional data. In mid-April, the head of the British Medical Association called for an urgent investigation into the possible greater vulnerability of black, Asian and minority ethnic people to COVID-19 following the pandemic-related deaths of ten doctors from these demographic groups, the first such deaths in the United Kingdom. An April letter to pharmaceutical companies working on coronavirus treatments from a group of US senators, including Bernie Sanders and Elizabeth Warren, similarly emphasized the critical need for comprehensive demographic and racial data to ensure that new treatments work for all Americans with the obvious premise being that a persons racial identity may play some role in their physiological response to medical treatment.

Similar narratives around racial genetics and biological determinism emerged forcefully during the 1980s and 1990s, when dramatic increases in gun violence, much of it involving young people associated with the burgeoning urban crack cocaine trade, gave rise to a moral panic that found its ultimate expression in the term superpredator. John DiIulio, a political scientist at Princeton University, coined the phrase in 1995 to describe a young juvenile criminal who is so impulsive, so remorseless, that he can kill, rape, maim, without giving it a second thought. The term became part of the popular lexicon, with law enforcement and elected officials on both sides of the aisle deploying it in service of promoting tough-on-crime policies. While peddlers of the superpredator theory never explicitly tied the phenomenon to genetics, the convergent discourse around crack babies children born to crack cocaine users certainly did. These children were unabashedly categorized as a bio-underclass, a generation of physically damaged cocaine babies whose biological inferiority is stamped at birth. In the case of both superpredators and crack babies, these youngsters were cast, both explicitly and implicitly, as urban African Americans.

Such talk of race science and biological determinism, whether clearly reactionary, as in the case of gun violence, or seemingly well-intentioned, as in the case of coronavirus, is troubling and wrongheaded. It is rooted in a long and sordid history in which black Americans have been labeled as inherently disease and violence-prone, among various other vicious and dehumanizing stereotypes. But as a purely historical social construction without genetic or scientific basis, race can be neither an explanation for violent behavior nor a risk factor for coronavirus infection or mortality. As sociologist Karen Fields and historian Barbara Fields note, however, belief in the biological reality of race outranks even astrology, the superstition closest to it in the competition for dupes among the ostensibly educated, a dynamic that permit[s] the consequence under investigation in this case, disparities in coronavirus and gun violence victimization among those defined as African American to masquerade among the causes. As historian and public health scholar Merlin Chowkwanyun warns, moreover, the belief in biological race can not only lead to claims of racial superiority or inferiority, but, less conspicuously, can also obfuscate a complex litany of explanations for . . . observable population differences.

Such is the case with the coronavirus, as it was with gun violence. Though dangerous biological theories of violence persist in some corners, the superpredator and crack-baby theories have long been exposed as the junk they always were. We should be mindful of these lessons as we think about the current coronavirus pandemic.

In comparison to the pernicious race science described above, other public health explanations offer a step in the right direction in accounting for high rates of coronavirus infection and death among African Americans. For example, the Centers for Disease Control and Prevention (CDC) has published a web page on COVID-19 entitled Health Equity Considerations and Racial and Ethnic Minority Groups that identifies economic and social conditions that are more common among some racial and ethnic minorities than whites that may be contributing to observed disparities. These include living conditions such as neighborhood population density and multigenerational households that make social distancing and quarantining more difficult, work factors such as employment in essential industries and lack of sick leave that heighten chances of exposure, lack of health insurance and access to affordable care that decreases the likelihood of early detection and treatment, and chronic health conditions such as heart and lung disease that increase the likelihood of severe symptomatology and death.

Similarly, public health has recently emerged as a nearly ubiquitous framework for understanding gun violence, promoted by everyone from the World Health Organization and the American Medical Association to Barack Obama and Donald Trump. While the 1996 passage of the National Rifle Associationbacked Dickey Amendment effectively banned the CDC from studying gun violence, the agencys information on youth violence though a much more widely construed phenomenon offers a generally useful proxy for gun violence, especially given the dearth of comprehensive data elsewhere.

Specifically, the risk factors for youth violence identified by the CDC include individual factors such as violence exposure and victimization, emotional distress, substance abuse, various types of problematic parenting and familial dynamics, association with delinquent peers, and residence in high-poverty neighborhoods. Though the CDC does not comment specifically on racial disparities in violence, the conclusion one is inevitably left with is that racial disparities in violence involvement are simply the result of a higher prevalence of these risk factors among African Americans.

One issue typical of the public health approach, however, is that there is little to no exploration of how these risk factors themselves come to be. Accordingly, there are few insights into the genesis of the racial disparities they purport to explain. Cure Violence, for example, the widely celebrated gun violence prevention model that likens violence directly to a pandemic disease, reduces violence to a learned behavior rooted in acute and chronic exposure to violence and broader community norms that promote such behavior.

While equating a pattern of social behavior the use of firearms to settle disputes and grievances to the workings of a submicroscopic infectious agent operating at the cellular level may benefit from a patina of medical credibility, such an account fails to provide any meaningful insight into the etiology of the behavior in question: Why does the disease of violence infect some communities but not others? Or, stated differently, why do some communities in a given city experience no homicides in a typical year, while nearby communities in the same city experience dozens of homicides?

Lacking any historically grounded explanation for such divergences, the public health model is susceptible to reframing these issues in cultural terms communities with healthy cultures, and therefore healthy norms, have low levels of coronavirus infection and gun violence, while those with pathological cultures and norms have high levels. At worst, these explanations simply reflect a reframing of biological race in polite language.

In any case, as historian Thomas Adams and political scientist Cedric Johnson argue, such accounts obscure issues that are firmly political and structural in nature by reinventing them as cultural phenomena, an approach that betrays a deep unwillingness to grapple with political and social causation. And if these phenomena are observed across groups with different cultural proclivities certainly, blacks are not the only victims of coronavirus or gun violence, nor do all blacks share a monolithic culture, for that matter then what we are witnessing is not race or culture, as such.

Yet this type of narrow and misplaced emphasis is evident in public healths proposed strategies for addressing these issues. The CDC promotes the view that the primary way to combat the coronavirus disparity among African Americans and other communities of color is by harnessing the strengths of these groups via shared faith, family, and cultural institutions that can empower and encourage individuals and communities to take actions to prevent the spread of COVID-19, care for those who become sick, and help community members cope with stress.

The role of the federal government, meanwhile, is limited to collecting data to monitor and track disparities, and the various recommendations for public health professionals, community organizations, and health care providers amount to little more than disseminating information on healthy practices and trying to connect people with resources. A similarly limited approach has been a selling point for Cure Violence, which proudly touts that the public health model is able to reduce violence in places with awful economies, without healing the economy, just as it has done with malaria, HIV, and other diseases throughout the world. (That the organization has often failed to actually reduce violence according to its model is an important aside.)

In short, in much of the public health discourse, structural inequality is reified, recast in terms of behavioral deficits to be rectified by information campaigns. While specific material circumstances that contribute to racial disparities may be acknowledged to varying degrees, the ultimate causes of these circumstances remain unaccounted for and are as likely as not to be explained as products of the alleged cultural pathologies of these populations themselves. This is not a helpful perspective for understanding these issues, nor for addressing them.

While the public health framework tends to present disparities in health outcomes as natural social facts devoid and undeserving of meaningful explanation, others espouse a ready and seemingly obvious explanation: racism (typically modified as structural, institutional, or systemic). For example, David Williams of Harvard Universitys TH Chan School of Public Health stated, We are looking at societal policies, driven by institutional racism, that are producing the results that they were intended to produce. Its been hard for Americans to understand that there are racial structural disparities in this country, that racism exists, offered Camara Phyllis Jones, an epidemiologist, family physician, and senior fellow at the Morehouse School of Medicine, adding, But COVID-19 and the statistics about black excess deaths are pulling away that deniability. Officials in Franklin County, Ohio, meanwhile, declared racism a public health crisis due to racial disparities in coronavirus deaths and other health outcomes. Other cities and counties have followed suit.

Racial disparities in gun violence have long been discussed in similar terms. In the 1980s and 1990s, this discourse coalesced around narratives that political scientists Willie Legette and Nikol Alexander-Floyd, respectively, refer to as the crisis of the black male and the Endangered Black Male. Though this specific language has largely disappeared from popular discourse on gun violence, its underlying premises have been widely internalized as cultural common sense, distilled in tropes about black-on-black violence and black urban neighborhoods as war zones. In recent years, however, the discourse of black male peril has reemerged forcefully in relation to a different kind of (typically) gun violence: police violence. Indeed, although acknowledgment of black female and LGBT victimization has been an explicit dimension of Black Lives Matter from its inception, the predominant understanding of police violence in the United States is one of black male crisis.

What has been almost entirely absent from the dominant public discourse on police violence is any meaningful class analysis. Yet even a cursory examination of the long and tragic list of high-profile police killings of black men reveals an unmistakable pattern: nearly all of these victims were poor or, at best, members of the working class. Indeed, their class status often directly precipitated their contact with police and/or shaped its trajectory: the use of an allegedly counterfeit $20 bill, the unlicensed selling of cigarettes or bootleg CDs, fleeing a police stop because of a suspected warrant for unpaid child support, vehicle violations caused and compounded by an inability to pay tickets or make needed repairs.

These dynamics, in turn, should be understood within a broader context of an approach to policing that emerges from an imperative to contain and suppress the pockets of economically marginal and sub-employed working class populations produced by revanchist capitalism. The now seemingly ubiquitous notion that racism or white supremacy is the lone factor driving police killings of black men obscures the complexity of these dynamics while also failing to explain police killings of whites, who comprise roughly half of all such victims.

To be clear, there is no doubt that black people and other people of color face racist discrimination in a wide variety of settings and situations that deleteriously affect their lives. There is also no doubt that such discrimination contributes to persistent racial disparities on nearly every adverse social indicator. But racism does not explain the existence of those adverse social indicators or the fundamental realities of inequality, which are produced by a political economy that concentrates incredible amounts of power and wealth in the hands of a small minority on one hand and fails to ensure a stable and dignified material existence for the majority of people, whatever their racial identities, on the other.

Patterns of inequality, then, are reproduced not only via racist discrimination, but via the logic of capitalist social reproduction the former of which, as historian Tour Reed points out, operates within the confines of the latter, not outside of it. A narrow focus on racial disparities and an understanding of them as solely by-products of an ostensibly all-encompassing, transhistorical racism, then, risks reifying broader patterns of inequality and the mechanisms by which they are (re)produced. After all, issues like coronavirus, gun violence, and police violence do not exclusively nor, in sheer numerical terms, even primarily affect African Americans. As political scientist Adolph Reed Jr and Merlin Chowkwanyun argue, disparity discourse thus fails to provide a holistic causal account of these phenomena and obscures the fact that inequalities that appear statistically as racial disparities are in fact embedded in multiple social relations.

As with gun violence, the routine appropriation of medical metaphors likening racism to a disease, an epidemic, or a public health problem further clouds the historical nature of racism and leaves unquestioned the political-economic processes that produce inequality, of which racial disparities constitute one abhorrent manifestation. Yet such a perspective dovetails well with the view that a transcendental racism is alone responsible for racial disparities if not the totality of suffering experienced by black people and, on the flip side, that racial disparities themselves are proof of that fact. This type of circular reasoning means that the discourse on racial disparities has the tendency to borrow from Barbara Fieldss appraisal of historical studies of whiteness to produce no conclusions that it does not begin with as assumptions.

In the end, racial disparities in coronavirus infections and deaths, as in rates of victimization by gun violence or police violence, for that matter cannot be explained by racialist biological determinism, simplistic references to behavioral or cultural norms, or an understanding of racism as operating outside of political economy and of disparities as distinct from broader patterns of inequality.

In the case of coronavirus, racial disparities cannot be divorced from an analysis of our fragmented, profit-oriented health insurance industry; the hollowing out of the public health care sector; a woefully inadequate residual-model welfare state; and eroding unionism, diminishing protections, and increasing precarity for working people. Similarly, racial disparities in gun violence must be understood as a by-product of the deplorable conditions in urban working-class black communities, including low levels of human and economic development, high levels of inequality, a weak and illegitimate state, and large populations of desperate young men involved in collective violence in other words, the same exact conditions associated with elevated levels of violence throughout the world. For their part, working-class white communities that have been similarly devastated by deindustrialization, job loss, and increasing despair in recent decades are facing a gun violence crisis of their own.

Rhetorical maneuvers likening gun violence and racism to pandemic diseases ultimately fail to illuminate the roots of these issues or their effects on variously raced populations. Indeed, even a meaningful appraisal of the societal and demographic impact of coronavirus an actual pandemic disease must be placed within the broader context of the political-economic factors described above. In the end, then, efforts to address racial disparities in pressing issues such as coronavirus, gun violence, and police violence should be understood as an indispensable dimension of a broader assault on the intensifying inequality and precarity facing working people, and as a part of political struggles to create a dignified material existence for all.

Excerpt from:
To Talk About Racial Disparity and COVID-19, We Need to Talk About Class - Jacobin magazine

Recommendation and review posted by Bethany Smith

Bison are currently gathering in the Hayden and Lamar Valleys, moving into massive aggregations of hundreds, if not thousands, of the iconic animals of Yellowstone National Park.

Massive bulls, some as large as 2,500 pounds, are fighting for the chance to breed. Challenges begin with bellows, as other bulls enter their territory. If the challenger replies, the bulls will begin to plow the ground, throw their huge frames on the ground and wallow, attempting to dust up.

From a distance, the clouds of dust look like the smoke from dozens of small fires, catching the sunlight in hues of yellow. What comes next is one of the most amazing displays of raw power in the park. The bulls move close head to head and unless one is willing to back down, the fight is on.

It will culminate then in essentially a fight to the death as they butt each others heads. Many bison are killed there, said Chris Geremia, Yellowstones top bison biologist. Theres really nowhere else in the world to see a breeding season like this with thousands of bison breeding.

Less than two centuries ago, there were as many as 30 to 60 million bison moving across the plains. Though there are far fewer now, the middle of a bison rut is still one of the most dangerous places to be in the park. The fighting can happen anywhere, including on the road through Yellowstones famous valleys. Still, visitors will clog pullouts and roadways during late July and the first three weeks in August some of the busiest weeks in the park hoping for a chance to see the spectacle.

Every year bison injure visitors, goring them or tossing them aside like rag dolls.

Give them some space, let them do their thing, Geremia said. Even if youre doing the right thing, theres a really good chance that those bison will move in your direction. We encourage people to get in their vehicles and move away Try and get to the next safest spot to observe.

Yellowstone doesnt keep track of property damage and injuries caused by bison. Most injuries happen when visitors, underestimating the speed and aggressive nature of the massive creatures, get too close. Bison can run at 35 mph and jump 5 feet in the air. Humans are no match for their athleticism. Every year the species cause property damage and injuries, Geremia said, so use your best judgement.

On Wednesday, the Park Service posted a video of one bison sending a rival partially airborne during a fight on a park road.

Geremia is currently working on research projects, including the effects of thousands of bison on the parks flora. The herd, estimated at approximately 5,000 individuals, is constantly on the move and constantly feeding. Bison migrate over 70 miles each year, Geremia said, and they walk more than 1,000 miles while searching for food during the year. Wolves and grizzly bears keep them moving, just like in pre-colonial times.

Weve realized that, as the bison population has gotten larger over the last decade, its changed the entire way that plants grow in the park, Geremia said So much so that it affects how spring green-up occurs across the park and how the plants ground down when it dries out in summertime.

The effects of the herds on plants is so dramatic, you can see a distinct difference in the way the park greens up in spring from space, he said. It was really stunning to me just because weve got wild bison roaming across the spaces.

Geremia is also testing genetics of the population and how it varies between these breeding areas. The PhD started as a field technician in 2002, collecting fecal samples and studying brucellosis in the population. He later became the program biologist and then was promoted to the bison team leader in 2018.

Bison make this ecosystem intact again, Geremia said. And the recovery of large predators and large herbivores is essential to making Yellowstone a full ecosystem, where youve got top predators and giant herbivores influencing what the land looks like.

Park visitors get the benefit and get to see this interaction happening, he added. Theres nowhere else in North America where you can see what you can see here.

As Yellowstones bison population has grown, park managers have taken actions to reduce the size of herd, culling hundreds of animals on an annual basis. Some have been transferred to Native American tribes.

This month, the InterTribal Buffalo Council will transfer 40 former Yellowstone bison to 16 tribes in nine states. These transfers will help develop and sustain tribally-managed herds while preserving the unique genetics and lineage of the largest and continuously free-roaming herd. The transfers are a victory of Native American tribes and represents the culmination of nearly 30 years of advocacy by the council on behalf of its member tribes, said council president Ervin Carlson.

Many Native American Tribes have been working to restore buffalo across the U.S., where they now number in the tens of thousands. Bison managed by Yellowstone National Park have never been interbred with cattle and will be used to help increase the long-term health of many populations across tribal lands.

The fight to protect Yellowstone bison is significant to many Native Americans, who disagree with management strategies which have led to the slaughter an estimated more than 10,000 since the early 1990s, according to the council.

The Choctaw Nation and Fort Belknap Tribes provided land and resources to support the development of bison quarantine facilities in 2018. The facility was built by the Fort Peck Tribes, funded in part by the council, and was approved for use in post-quarantine assurance testing by the State of Montana. Since then, the council says, quarantine operations have saved over 200 bison from slaughter.

Here is the original post:
A fight to the death Bison rut is on in Yellowstone - Powell Tribune

Recommendation and review posted by Bethany Smith

PULASKI How does life face the onslaught of a force as powerful as death, totally unnecessary death? Coronavirus is schooling us in that question now, and we are a powerful force in ourselves. But, how does a little bird face it? A five-inch, four-ounce, little thing against all of nature and the power of man. A little life that 90 years ago numbered 1,000 pairs, but today only numbers 64. How does a little bird stand up to that?

Claire Nellis is 26, a Pulaski native, a 2015 graduate of Paul Smiths College majoring in wildlife sciences and fisheries and presently the Piping Plover Project Coordinator for the New York State Office of Parks, Recreation, and Historical Preservation on a grant from the U.S. Fish and Wildlife Service to save that little bird, the piping plover, a tiny shorebird, somewhat similar to the sandpiper, that has been decimated to the point of near-extinction, earning it an inglorious spot on the federal endangered species list, here on Sandy Island Beach, the only place in the state it has returned to make its stand against annihilation. And Claire Nellis, and an impressive array of others, are here to help it make that stand.

Just as the plovers have returned to Sandy Island Beach, Claire Nellis has returned to her hometown. For the last five years, shes been far from home, working always with wildlife, in Missouri for three years working with prairie chickens and turkeys and before that, in Idaho with owls. Now, since May 21 of this year, shes back.

I grew up in Pulaski, she said, and I kind of took the uniqueness of the beaches that we have for granted. I didnt realize how rare they were. And its really an amazing ecosystem. Its fragile and resilient in lots of ways. Its changed a lot over time. Im thrilled to be part of their story of recovery here, and its great to be working on conservation in my hometown.

The plovers, she said, returned to Lake Ontario in 2015 at Lakeview Wildlife Management Area. A local birder spotted one and couldnt believe their eyes, because theyve been missing for 30 years. They notified DEC and let them know. And then in 2016, there was a pair that nested at Sandy Island Beach State Park, which is where I work, and another pair nested at Lakeview Wildlife Management Area, which is just north of the park, in the same habitat. So, since they were there, U.S. Fish and Wildlife Service got involved as a federally endangered bird. The federal agency stepped in. Then 2017, there were prospecting adults (plovers) that checked out the area, but it was such high water, they unfortunately werent able to nest. And then, the Piping Plover Project Coordinator position, which is the position Im in now, started in 2018. Alivia Sheffield filled that position the first two years, and she did a lot of really phenomenal work, a lot of the beginning groundwork of monitoring them and building relationships with people out at the beach and doing a lot of outreach and education. Ive benefited a lot from all of her hard work.

The advent of that one nesting pair was, of course, a major development and defining moment in the nationwide work to bring the piping plover back to numbers representative of a healthy population. But just as one swallow does not a summer make, one pair of piping plovers does not signal the end of their plight. They are a fragile little bird, and it takes a lot of the right conditions to see to it there will be more of them.

Theres still only one pair nesting here unfortunately, Nellis said. The first year, in 2016, they lost their nest due to fox predation, and then in 2018, to help compensate for that, they were able to put up a nest exclosure, metal fencing, kind of like chicken wire, but large enough that the plover can get back and forth through but a fox or a raccoon wouldnt be able to. Its probably about five or six feet across, she explained, and it goes all the way around the nest, and it has a top layer to it as well, so that they (predators) cant just climb over.

That helped, and the plovers have been fruitful and multiplied. In their own rather humorous way, the pair comes together, seemingly for life, in a courtship ritual Nellis described.

The male actually helps with nest brooding and care, she said, and he will lay his belly on the ground and use his back legs to kick out a scrape. Its really just a little indentation in the sand. And then the female will watch him do that and come along and sit in it and either approve or more often, disapprove. Once they pick a scrape that they like, theyll line it with shells, and then just lay their eggs right in that. They usually lay four eggs.

Im not sure what her criteria are, Nellis said of the female plover, but he will often make many scrapes before she decides which ones the best. Its just part of their courtship. I dont know if its the placement on the beach or how deep he scrapes it or what, but sometimes its right, and usually its not.

After that, the pair stays together, at least in a sense, more like a married couple that takes separate vacations. Weve had the same pair, and they have individual bands that mark them, so we know whos who. So, the last three years, weve had the same adults nesting at Sandy Island.

Then comes the turn in the weather, and the plovers, who fly very little while nesting and living at Sandy Island Beach, fly long distances, separately, to the warm south.

They migrate south anywhere from North Carolina to the Bahamas, but primarily in Georgia and Florida, Nellis said. Theyll go to very similar habitat of the open beach where they can run down to the shoreline and eat invertebrates and then run back up into dunes for protection.

They migrate very long distances, so, they are good flyers, but theyre also good at walking. Their anatomy allows them to mostly be running on the ground rather than exerting the effort to fly everywhere.

While migrating, she said, they do stop over at beaches along the way. So sometimes well get reports that our female, shell leave our beach up here in Pulaski and then stop at a beach in Pennsylvania and feed for a day or two to refuel. And then shell continue her way south.

They all migrate separately. The female typically leaves first, and then, the male will leave after, and then the chicks will migrate.

So, the adults will leave, and the chicks will stay and continue feeding and growing and practicing flying for a little while before they take off south. Amazingly, they know where to go. And often theyll wind up in similar areas, Nellis said. Theres been research thats shown they can end up even within kilometers of each other. And they dont necessarily winter together either. They might not meet up down there even if they happen to be on the same beach, its not like theyre spending quality time together. Then they migrate north again and meet up sometimes hours or days apart at the same beach.

Sometimes theyre in different states (during the winter), Nellis continued. I think our pair, we havent seen the male, and the female was spotted in Georgia, and one of the chicks was spotted in Florida.

And then they individually head back north about the same time and meet up back at the same beach.

Our pair has done that three times, Nellis said.

Of course, you cant monitor and care for these little creatures and leave them as just anonymous blobs of feathers. So, they name them.

Theyve all got names, Nellis said. The first year that the male and female came they got named Aragorn and Arwen, and then their chicks all had Lord of the Rings-themed names too. 2019, they went with Star Wars-themed names, so they named the chicks Chewie, Yoda, and Leia. It was pretty exciting because Chewie was spotted down in Florida, and they reported that to us, and then she attempted to nest in Canada near downtown Toronto at a beach, and she stopped back over at Sandy Island Beach on her way south, July 4th, of all days, busy day. Thats the first time weve had a chick return to the habitat at Sandy Island. Even though she didnt attempt to nest, just stopping over was good to see her.

The chicks hatched June 14 this year, and thats about average. Ninety percent of chicks hatch between June 3 and July 14. Im glad that they successfully fledged and have officially migrated. The days are already starting to get short, and Im not sure why shore birds tend to migrate sooner than song birds, but evenings are starting to get colder, and they just head out as soon as theyre able. The adults arrived in early May. The female left July 10, and then the male left July 13. We had two chicks successfully fledge. This year they were named Fleetwood, Buckingham, and Stevie Nicks. Unfortunately, we lost Fleetwood before the female even left, I think the first week of July, so the chick was about two weeks old. We dont know what happened, probably a natural predator like an owl or possibly a fox or a raccoon got it. It couldnt fly, so we know something happened to it on the beach. Mostly its predation that gets them. Predation is a pretty heavy threat for them, and also, loss of habitat and the pressure of habitat use. In the 1930s, when their populations started to decline, it was from beachfront home construction and beach use. So, especially, off-road vehicles later becoming popular would just go right over them or their nests. And as that was mitigated in the 1980s, as they were listed as a federally endangered bird under the Endangered Species Act, theyve gotten more protections for their habitat, and so, theres no longer off-road vehicles allowed, beachfront construction has slowed down. But just the presence of people and dogs on the beach has increased significantly, and so, having less area available to them to be able to forage, because they eat most of the day, theyre really small birds, and theyre just eating invertebrates, so getting to their food source is really important, and the stress of feeling like theyre constantly being chased by people or dogs around can decrease their survivorship. And so, at Sandy Island Beach, we have part of their habitat, its about 100 meters of shoreline thats roped off for them. So, people can still walk by, but they cant set up and hang out there. And so, that keeps some area available to them.

In the 1930s, Nellis went on, at our beach there were 14 nesting pairs. In all of the Great Lakes, I think there were right around 1,000. So, having only 17 pairs in 1984, they declined pretty quickly. But theyre slowly making a comeback. The goal for de-listing them, or getting them off the endangered species list, is to have 150 breeding pairs, and 100 of them need to be in Michigan and then 50 more spread throughout the Great Lakes. Were still about 90 pairs away from that. I would be thrilled to be unemployed from this position in two or three years, if we could get that many pairs, but its likely that theyll still be endangered.

They need that open beach, she said, so that their little legs can navigate through it. A lot of dune stabilization efforts are important to hold the dunes in place. Without some vegetation there, they just blow away and erode. But over-vegetation can be hard for the plovers to navigate. Storms at certain times of the year are good, because it washes out some of that vegetation and makes more habitat available, but if theres a storm when the chicks are very young, they cant stay dry and warm, and they can die from that. If their nest on the ground gets washed out and flooded, thats problematic as well.

Once they settle, they typically stay on that beach, and they can travel up to a mile. But when they are trying to find good habitat for the first time, many times, theyll go back to their original birth place where they were hatched, but obviously, thats not what ours did, so a certain percentage of them fly around and try to find other suitable habitat. Theres a 17-mile stretch of the dune wetland ecosystem along eastern Lake Ontario. It starts with Deer Creek Wildlife Management Area, which is just south of Sandy Island, and goes north up to Eldorado and Black Pond Wildlife Management Area. So, they would prospect along that. But they also could fly all the way across Lake Ontario and check out beaches in Canada. The main population of Great Lakes piping plovers are in Michigan. 2018 was the first year that there were piping plovers on all the Great Lakes again.

If I got to pick and control things, Nellis said, which I dont, I would love for one of our chicks to come back and find a mate from an area such as Michigan or Canada to increase the genetics a little bit. So, its possible that two chicks from a different year or Aragorns brother, who we dont have a name for, he has visited the beach as well, and not stayed around, but he attempted to nest with one of our chicks in Canada. So, kind of funny in human terms that our chick tried to nest with her uncle. I know genetically theres a possibility that it could be detrimental, but at this point, with such a small population, it would overall still be a good thing if they were able to nest together.

They nest on areas that people frequent, and often large volumes of people, and they can still successfully nest, which is pretty impressive. And sometimes, well see people walking by them, and the person doesnt notice the bird, and the bird just continues foraging. But more often than not, the person doesnt notice the bird because theyre just enjoying the beach day, and the bird is running away from them as a perceived threat, or if the chicks are there, theyll do that broken wing act, where they kind of put their belly on the ground and flop their wings around, making it look like they cant fly away, but theyre trying to. And so, that would attract the predators attention, and it would go towards them rather than the chicks, and then it would make a short flight and do it again that would keep leading the predator away, and then fly back once the predators far enough away.

Both the male and female do that behavior.

We observe it more often in the males than the female, Nellis said. The female tends to not be quite as good of a parent as the male. But the male is really protective, and he will do the broken wing act, he will brood the chicks in his feathers to keep them warm, and hell also mob gulls. If a gull is getting too close to one of the chicks, hell fly over it and kind of peck at it. Gulls dont actively seek the chicks out, but gulls are such generalists and opportunists that if one is nearby and they could pick it up and eat it, they definitely would. Weve been fortunate that that hasnt happened with our pair in New York, but in other populations, its been demonstrated.

Plovers are primarily ground-dwelling shore birds. Thats one of the main distinctions between shore birds and sea birds. Sea birds, like terns and seagulls, will fly out and get fish, and then kind of land on the beach to rest or to eat. But shore birds, like plovers or sandpipers, will have that behavior where they run down the beach and eat at the shoreline, and then they run back up the beach to rest.

That running style is one of their distinctive traits.

Once you know what youre looking for, you can pick them out on the landscape, Nellis said, but oftentimes when Im talking to the public, if they havent seen them before, we have to get a spotting scope out to really zoom in on them. They have the same color feathers as the sand, so they blend in real well, and theyre also very small, and I think people are so used to looking at seagulls or the larger terns that fly around out there, a small bird just running along the shore is hard to pick out. Especially, they have a run, stop, movement where theyll run a short way and then kind of stop and look around or squat down in the sand even and then run again. So, they can be real hard to pick out. Even when I first started out working with them this spring, I had a horrible time. I was like, I cant believe this is my job and I cant even find the bird. But once you know what youre looking for, you kind of have that search image. And the chicks, especially, are even more difficult to find. When they first hatch, they are about the size of a cotton ball, and they weigh the same as two pennies. Theyre just so tiny, and incredibly well camouflaged. Their behavior also, when they get scared, is to flatten against the sand. They just really disappear right into it, which works great for aerial predators, like merlin or other hawks, but for ground predators, or even ground-going mammals like ourselves and dogs, even if theyre not maliciously seeking out the bird, it perceives us as a threat, it squats down, we dont see it, and they can easily be stepped on.

And the adults arent too big either.

Theyre very small, Nellis said. What we tell people on the beach, to give them an idea, is an adult weighs the same as a stick of butter.

But at least an adult plover has a chance of getting out of your way.

The adults will fly away once you get close, Nellis added. But the chicks cant fly. They can walk around within the first few hours of birth, so, theyre mobile but also vulnerable since theyre not in that nest. But they cant fly until about 20 to 25 days after they hatch.

All the plovers are uniquely banded with different-colored bands and a metal band on the other leg with a longer individual identification number on it.

They dont have a radio tracker on them, Nellis said. They just have the individual bands. So, if theyre traveling around to other beaches and not staying long, and they dont get sighted by a birder or a researcher thats up there, we dont really know where they go.

But in one way somewhat similar to salmon, plovers tend to return to where they were born. They have pretty high site fidelity, as its referred to, Nellis said.

That also means, she said, returning to where theyve successfully nested year after year, as well. Where youve been successful, you tend to head back. And maybe thats true for Claire Nellis too. All she knows for sure is, shes proud of her community.

Because this land was originally private, and so many of those families still live on the pond and enjoy that area, they all have a sense of ownership and pride in taking care of it, and thats something that I am proud of Pulaski and my community recognizing, she said. And having the piping plovers return to this area, theyre the only nesting pair in New York state, I think is really special and really a marker of how hard the community has worked to improve the ecosystem.

Nellis credits many others with helping her in this project.

We work with SUNY ESF and Jonathan Cohens lab, Nellis said. He has a permit that allows us to capture them and band them. Were only allowed to handle them for half-an-hour before they have to be released back to the parents. Theyre a well-oiled machine. We were fortunate enough to observe and help out a little bit, but he had graduate students come out whove worked with them before, capture them and place bands and then release them again.

Nellis also credited the U.S. Fish and Wildlife Service; the Onondaga Audobon Society; New York State Department of Environmental Conservation; Jonathan Cohens graduate Ph.D. student, Allison Kocek; Robyn Niver and Tim Sullivan, both at U.S. Fish and Wildlife Service; Irene Mazzocchi at the Department of Environmental Conservation; my supervisor, Tom Hughes, the regional biologist; Kelly Morrissette, the manager of the state park; and all the members at the Eastern Lake Ontario Dune Coalition have been really helpful, she said, especially noting Tom Hart, Sandy Bononno, and Patricia Schulenberg. Were lucky to have an organization like that that cares so much and helps with getting everybody on the same page.

Right now, its very likely there are more people trying to save the piping plover than there are piping plovers. But in the face of what oftentimes seem like overwhelming odds, the persistence of dedicated people and the resiliency of nature combine to perform what almost seems a miracle. That miracle may very well be in the making right now at Sandy Island Beach.

More:
The piping plover making a comeback at Sandy Island Beach, Pulaski native who's come home to help - NNY360

Recommendation and review posted by Bethany Smith

Local researchers are asking Southeast Alaska residents to keep an eye out for a white killer whale, seen recently near Petersburg, and believed to be part of a pod known to travel as far north as Haines.

Id like people to know how rare a white killer whale is and how wonderful it is being so close, said Stephanie Hayes, a Petersburg-based doctoral student with the University of Alaska Fairbanks. We can actually record and learn more about these rare killer whales.

Tluk, as whale T046B1B is known, is about 2 years old and is believed to be a male. However, since the animal is still a juvenile, Hayes said researchers cant be entirely sure of the sex yet. Hayes said Tluk is a regular around Vancouver Island, but he was seen recently near Kake. She was able to snap a photo of the whale with its pod near Petersburg on Aug. 6, and on Monday Tluk was seen again near Petersburgs Sandy Beach, she said.

The name is Coast Salish for moon, Hayes said, and when hes seen in the water, Tluks whiteness makes him look almost like hes glowing, something which might be a problem later in life. Killer whales are hunters, Hayes said, and being easily spotted isnt exactly advantageous to a predator.

Youre kind of a beacon, she said of being a brightly pigmented hunter. Its going to be more difficult to hunt a sea lion if it can see you coming.

Since Tluk is still only a juvenile, he hasnt strayed too far from his pod, Hayes said, but once he does its unknown if hell be accepted into other pods. Some males leave their home pods and join others in their lifetime, but not all whales are accepted by other pods. These males can become what Hayes called loners, who live mostly independently. But those animals dont glow brightly in the water, and can easily hunt on their own. Whether or not other pods will accept a white whale, or if Tluk will be able to hunt on his own an open question, she said.

[Shoes stand in for protesters at Capitol]

The scarcity white killer whales in the world meant Tluks presence is Southeast presented an unlikely opportunity to collect data not just on white killer whales, but orcas in general, Hayes said. There are still a lot of unknowns about killer whales in general which makes knowing what might happen to Tluk hard to predict.

Tluk is not fully white, and doesnt have pink eyes, which leads Hayes to believe he probably doesnt have albinism, a condition defined by a complete lack of pigmentation. Hayes believes Tluk has whats called leucism.

With leucism theres a lack of vibrancy in the pigmentation, Hayes said. The colors are more muted and not fully expressed. You can still see the spots but it looks like a ghostly color.

Leucism is certainly a possibility, according to Brad Hanson, a wildlife biologist with the National Oceanic and Atmospheric Administration Fisheries Department, but because theres so little data on white killer whales its too soon to tell.

There was a white killer whale named Chimo at Sealand of the Pacific, a former aquarium near Victoria, British Columbia, in the 1970s, but it is still hard to say what was causing the whitewashing of the orcas skin.

More white killer whales have been reported in the past few decades, according to Hayes, and there is some research to suggest leucism was ultimately the result of increased inbreeding due to declining whale populations. Theres not yet enough data to be conclusive, but genetic research on whales has improved, she said, and researchers in Switzerland have theorized increased instances of leucism could be the result of a lack of genetic diversity.

Its difficult to know what is considered typical for killer whale populations as good data is sparse and only goes back a few decades, she said. The lack of general knowledge about killer whales was something Hanson noted when asked about the potential link between inbreeding and leucism. It is an interesting theory he said, but wasnt sure he agreed.

My perspective is that because theres been increased effort in looking at killers whales, it wouldnt surprise me were detecting more, (instances of abnormalities), Hanson, whos based in Seattle, said in a phone interview Monday.

All the genetics on transient populations is unclear, we dont have a definitive idea of what the stock structure is, he said, referring to transient orcas, who hunt mammals and are biologically different from other kinds of killer whales.

We did detect some inbreeding in one of the pods. I dont think we have enough information to evaluate it at this point, he said.

But collecting information is exactly what Hayes says people can help do.

[Four whales struck by vessels this year in Southeast]

Its super important and super easy, she said.

Theres a number of websites tracking whale movements and a lot of the data is collected by everyday people uploading pictures of when and where they saw a particular whale.

Hayes mentioned HappyWhale.com as a site where members of the public can upload pictures of whales with time, date and location and that data will become public information for researchers around the globe. Pictures of dorsal fins on animals backs are best, Hayes said, as scientists use those markings to identify individual whales.

White whales or not, tracking whales is useful information and helps NOAA better understand habitat use, Hanson said, giving a better picture of the overall health of the ecosystems.

Tluk and his pod are here to eat, Hayes said, and where they go is entirely up to them. Historically Tluks pod has come to Southeast, but this is the first time the white whale has been seen in Alaskan waters, she said.

We know the pod has been coming up and we can keep an eye out for them, she said. We have a chance to actually see the white killer whale. It could be headed your way.

Contact reporter Peter Segall at psegall@juneauempire.com. Follow him on Twitter at @SegallJnoEmpire.

Go here to read the rest:
Rare white killer whale spotted in Southeast - Juneau Empire

Recommendation and review posted by Bethany Smith

Rs 599, 282pp; HarperCollins

Prairie voles (Microtus ochrogaster) are said to be the paragons of monogamy. These brown mouse-like creatures, smaller than a palm squirrel, are among only 3 to 5 per cent of about 5,000 mammals to stick to one partner all their lives. When one of a couple dies, its mate most often lives a solitary life. But some studs give the lie to their species monogamous lifestyles. They trespass upon other voles home ranges, sneaking sex and scrapping with strangers. Female partners in stable relationships arent above having a casual fling. Their regular mates dont father even as much as a quarter of the litters. Still, a majority stick with their first sex partner, and thats a rarity in the animal world.

Philandering males of these small North American rodents hit the reproductive jackpot, producing more babies than their monogamous counterparts. But being unfaithful is not all fun and frolic. While these males are gallivanting, their lonely mates may also seek sex with others. These cuckolded males that are busy cuckolding others are more likely to raise a rivals offspring. Neither monogamy nor polygamy has an edge, and prairie voles practice both.

What makes some stick to one mate and the others wander?

Vasopressin, a hormone produced by the brains hypothalamus, influences social behaviour such as aggression, bonding with mates and care of offspring. It suffuses the brains of monogamous voles that have more vasopressin receptors (V1aR) in the ventral pallidum, the reward-seeking part of the brain. It is the same with faithful men. When receptor rich voles have sex for the first time, they imprint on their partners and thereafter stay true to them.

Meadow voles (Microtus pennsylvanicus), closely related to prairie voles, are promiscuous. By injecting vasopressin receptors into the males brains, researchers turned them monogamous.

The receptors were not the only things keeping male prairie voles in line. A lot has to do with their sense of geography, say Steven Phelps of the University of Texas at Austin, US, and his colleagues. They discovered rodents with more vasopressin receptors in the brains retrosplenial cortex, known for its role in memory and navigation, stayed within the confines of their homes. These rodents recalled sites where they had fights with rivals and avoided them.

The ones with fewer vasopressin receptors had a poorer understanding of their territories. They wandered over large areas, intruding on others territories and perhaps only dimly recollecting where their nests were located. The result: promiscuity.

A meadow vole. (Shutterstock)

Why didnt the prairie voles stick to either monogamy or polygamy? Mariam Okhovat and other students in Phelps lab used genetics in the lab combined with radio telemetry data gathered in a previous study to find out. They examined the gene avpr1a, known for predicting sexual fidelity in males and encoding the vasopressin receptors V1aR.

The specific arrangement of the four nucleotides in a DNA sequence is called encoding. It is the recipe for producing a particular protein that plays a unique role. In this case, the gene avpr1a produces a protein that acts as a receptor for vasopressin.

Not only did the number of V1aR in the ventral palladium and retrosplenial cortex anticipate male behaviour, but variations in the sequence of the gene also mattered.

The researchers discovered avpr1a comes with two alleles that they call HI and LO. The structure of the V1aR produced by the HI and LO alleles is the same, but they produce different amounts, says Okhovat. Males with the HI allele producing more vasopressin in the retrosplenial cortex were faithful and stayed within the bounds of their home range. The ones with the LO allele produced low levels of the hormone in the retrosplenial cortex and bumbled far out of their territories. Although the researchers noticed this correlation, this relationship between geography and vasopressin in the retrosplenial cortex hasnt been confirmed.

The two alleles didnt affect the amount of V1aR receptors in the ventral palladium, which regulates motivations, emotions and behaviour. The gene variations only affected receptors in parts of the brain involved in remembering places and sexual fidelity.

Phelps says his team was shocked by what they found. This brain variation isnt just there by chance. It isnt random. Natural selection had maintained the alleles in prairie voles for a long time so they had to benefit the species.

Janaki Lenin(Courtesy HarperCollins)

Since these effects are stronger in captive voles than in wild ones, the researchers say the traits cannot be explained by heredity alone. Environment and population may also influence the degree of males faithfulness.

Like many rodents, their populations boom or crash depending on food supply. Numbers explode at feast times, and home ranges shrink in size, with more than 600 rodents jammed in a hectare. Such situations are a perfect playground for promiscuous voles with little sense of territory, and a headache for possessive male voles, keen on keeping their mates away from strangers charms.

During famines, vole populations crash, leaving only one or two in a hectare. Those with better navigation and memory skills are at an advantage. They dote on their partners, defend their territories and mates from philandering males, and make successful parents.

Extending these conclusions to human behaviour is tempting, but research hasnt advanced that far. A 2014 study of 7,400 twins in Finland is the latest to suggest genes could influence faithfulness. It is possible vasopressin receptors control fidelity in women and, to a lesser degree, in men. Surprisingly, oxytocin, commonly thought to be at work when women bond with their partners, seems to have little effect. Philandering in humans may have some biological basis, but it is complicated by personality and environment.

Of his findings in voles, Phelps says, When it comes to social behaviour, maybe there isnt a normal brain. Many genes may have subtle variations so that individuals of a species can respond with flexibility to circumstances.

Wandering voles go astray in more ways than one.

View original post here:
Excerpt: Every Creature Has A Story by Janaki Lenin - Hindustan Times

Recommendation and review posted by Bethany Smith

Global Male Breast Cancer Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Global Male Breast Cancer Market Report offers an entire study of the Impact of COVID-19 on Male Breast Cancer Market, Industry Outlook, Opportunities in Market, and Expansion By 2025 and also taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of this also as a future scenario of the worldwide Male Breast Cancer industry. Research techniques like PESTLE and SWOT analysis are deployed by the researchers. They need also provided accurate data on Male Breast Cancer production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding of the general existing and future market situation.

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Male Breast Cancer Market:

Male Breast Cancer Market competition by top manufacturers/Key player Profiled:Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare

The study objectives of Male Breast Cancer Market report are: 1.To identify opportunities and challenges for Global Male Breast Cancer.2.To provide insights about factors affecting market growth. To analyze the Male Breast Cancer market based on various factors- price analysis, supply chain analysis, SWOT analysis, etc.3.To identify and analyze the profile of leading players involved within the manufacturing of worldwide Male Breast Cancer.4.To provide country-level analysis of the market regarding the present Male Breast Cancer market size and future prospective.5.To examine competitive developments like expansions, new product launches, mergers & acquisitions, etc., in Global Male Breast Cancer.6.To provide a detailed analysis of the market structure alongside forecast of the varied segments and sub-segments of the worldwide Male Breast Cancer market.

By Types, the Male Breast Cancer Market can be Splits into:

MedicationChemotherapyOthers

By Applications, the Male Breast Cancer Market can be Splits into:

HospitalsClinicsOthers

The global Male Breast Cancer market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Click Here For Best Discount: https://www.reporthive.com/request_customization/2414230

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

Global Male Breast Cancer Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Male Breast Cancer Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons To Buy: Make strategic business decisions using in-depth historic and forecast market data associated with the Male Breast Cancer market, and every category within it.Extensive price charts draw particular pricing trends within recent yearsPosition yourself to realize the most advantage of the Male Breast Cancer markets growth potentialTo understand the latest trends of the Male Breast Cancer marketTo understand the impactful developments of key players within the market, their strategic initiatives and comprehensively study their core competencies

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2414230

Table of Contents

Report Overview:It includes major players of the global Male Breast Cancer Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Male Breast Cancer Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Male Breast Cancer Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Male Breast Cancer Market by application, it gives a study on the consumption in the global Male Breast Cancer Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Male Breast Cancer Market are profiled in this section. The analysts have provided information about their recent developments in the global Male Breast Cancer Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Male Breast Cancer Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Male Breast Cancer Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Male Breast Cancer Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Original post:
Trending Today Corona impact on Global Male Breast Cancer Market 2025: Outlook by Key Companies and Growth Forecast 2020| Pfizer, Roche,...

Recommendation and review posted by Bethany Smith

Global Male Breast Cancer Treatment Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Global Male Breast Cancer Treatment Market Report offers an entire study of the Impact of COVID-19 on Male Breast Cancer Treatment Market, Industry Outlook, Opportunities in Market, and Expansion By 2025 and also taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of this also as a future scenario of the worldwide Male Breast Cancer Treatment industry. Research techniques like PESTLE and SWOT analysis are deployed by the researchers. They need also provided accurate data on Male Breast Cancer Treatment production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding of the general existing and future market situation.

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Male Breast Cancer Treatment Market:

Male Breast Cancer Treatment Market competition by top manufacturers/Key player Profiled:Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare

The study objectives of Male Breast Cancer Treatment Market report are: 1.To identify opportunities and challenges for Global Male Breast Cancer Treatment.2.To provide insights about factors affecting market growth. To analyze the Male Breast Cancer Treatment market based on various factors- price analysis, supply chain analysis, SWOT analysis, etc.3.To identify and analyze the profile of leading players involved within the manufacturing of worldwide Male Breast Cancer Treatment.4.To provide country-level analysis of the market regarding the present Male Breast Cancer Treatment market size and future prospective.5.To examine competitive developments like expansions, new product launches, mergers & acquisitions, etc., in Global Male Breast Cancer Treatment.6.To provide a detailed analysis of the market structure alongside forecast of the varied segments and sub-segments of the worldwide Male Breast Cancer Treatment market.

By Types, the Male Breast Cancer Treatment Market can be Splits into:

MedicationChemotherapyOthers

By Applications, the Male Breast Cancer Treatment Market can be Splits into:

HospitalsClinicsOthers

The global Male Breast Cancer Treatment market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Click Here For Best Discount: https://www.reporthive.com/request_customization/2414231

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

Global Male Breast Cancer Treatment Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Male Breast Cancer Treatment Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons To Buy: Make strategic business decisions using in-depth historic and forecast market data associated with the Male Breast Cancer Treatment market, and every category within it.Extensive price charts draw particular pricing trends within recent yearsPosition yourself to realize the most advantage of the Male Breast Cancer Treatment markets growth potentialTo understand the latest trends of the Male Breast Cancer Treatment marketTo understand the impactful developments of key players within the market, their strategic initiatives and comprehensively study their core competencies

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2414231

Table of Contents

Report Overview:It includes major players of the global Male Breast Cancer Treatment Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Male Breast Cancer Treatment Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Male Breast Cancer Treatment Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Male Breast Cancer Treatment Market by application, it gives a study on the consumption in the global Male Breast Cancer Treatment Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Male Breast Cancer Treatment Market are profiled in this section. The analysts have provided information about their recent developments in the global Male Breast Cancer Treatment Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Male Breast Cancer Treatment Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Male Breast Cancer Treatment Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Male Breast Cancer Treatment Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original here:
Global Covid-19 impact on Male Breast Cancer Treatment Market Report 2025 by Global Market Insights, Outlook and Driving Trends 2020| Pfizer, Roche,...

Recommendation and review posted by Bethany Smith

Efforts to get the two to breed had not worked.

He was the equivalent of a 70-year-old man, so of course you dont expect the sperm to be all that good, said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysias rhinos.

It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this.

ACROSS THE BORDER

Indonesias environment ministry disputed accusations of cross-border rivalry as a reason why Malaysias rhinos died out, saying talks continue on ways to work with conservationists in the neighboring southeast Asian nation.

Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country, said Indra Exploitasia, the ministrys director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

Excerpt from:
Scientists hope to bring Malaysian rhinoceros back from extinction with stem cell technology - National Post

Recommendation and review posted by Bethany Smith

Whats wrong with my skin? Identifying skin conditions, skin disorders, skin cancer and more

Is it acne, a rash or maybe something more serious? Skin disorders can vary in both symptoms and severity. Some skin conditions are minor, some are serious but treatable, and others, like skin cancer, can be life-threatening. Here are 18 common (and a few less common) skin conditions with photos to help you ID them. Remember to always reach out to your physician for a proper diagnosis and treatment.

Acne | Actinic keratosis | Basal cell carcinoma | Blisters | Carbuncle | Cellulitis | Chicken pox | Cold sores | Contact dermatitis | Eczema | Hives | Latex allergy | Lupus | Measles | Melanoma | Psoriasis | Rosacea | Squamous cell carcinoma

Suffering from acne? Youre not alone. Acne is the most common condition dermatologists treat 40 to 50 million Americans struggle with acne at any given time.

Acne can show up almost anywhere on the skin as blackheads, papules and pustules or pimples, cysts and nodules

Acne starts when dead skin cells dont shed properly and clog your pores.

Some acne can be treated with over-the-counter products, while others require professional help, including prescription medication and treatments.

Read more about acne and how to treat it.

These precancerous lesions often appear as rough spots on the skin. Actinic keratosis is common, but if left untreated it can turn into squamous cell carcinoma.

The appearance of actinic keratosis can vary from bumps that look like pimples or acne to rough lesions that are red, pink or gray.

When cells in the skin called keratinocytes are damaged by UV rays, it can cause actinic keratosis.

While not always necessary, treatments may include removal of the actinic keratosis with liquid nitrogen, chemical peels, scraping or other therapies.

Read more about actinic keratosis and how to treat it.

Basal cell carcinoma is the most common type of skin cancer. It affects approximately 2.6 million people in the U.S. each year. Do you know how to spot it?

Basal cell carcinoma is much more common in people who have light skin. Symptoms tend to be the same color as the skin or pink. Its important to look for any changes in your skin.

Exposure from ultraviolet rays (UV) from the sun or indoor tanning is a primary cause of basal cell carcinoma.

Your dermatologist may be able to remove a basal cell carcinoma tumor when doing a biopsy. Sometimes a Mohs surgery is recommended.

Read more about basal cell carcinoma and how to spot it.

A common skin condition, most people develop blisters once in a while.

Blisters are small, painful sacs of fluid.

Blisters can be caused by friction, such as by a shoe rubbing against the skin, or by sunburns, heat or skin diseases.

Blisters tend to heal on their own, but a blister can be drained if its too painful.

Read more about blisters and how to treat them.

Sometimes confused with a spider bite, a carbuncle is a group of boils that stem from an infection of the skin and are connected to each other.

Red, tender bumps, or boils, that contain pus are signs of a carbuncle. Carbuncles can eventually rupture, and pus will leak out of them.

A bacterial infection, such as Staphylococcus aureus, is often the cause of a carbuncle.

If a carbuncle is small, you may be able to treat it at home with warm compresses and bandages. Otherwise, your dermatologist can make an incision to drain the pus.

Read more about carbuncles and how to treat them.

Cellulitis is an infection of the skin in which the skin becomes red and swollen. It typically occurs after you get a cut or wound.

When you have cellulitis, an area of your skin often on one of your legs becomes red, swollen, warm and possibly painful.

Cellulitis can be caused by two different types of bacteria: streptococcus (aka strep) or staphylococcus (aka staph).

Antibiotics like penicillin, cephalosporin or erythromycin are normally used to treat cellulitis.

Read more about cellulitis and how to treat it.

Also called varicella, this highly contagious disease mostly strikes children.

A fever may precede it, but the unique chicken pox rash appears on the skin with itchy blisters that look like lots of little dew drops.

The varicella-zoster virus (VZV) causes chicken pox as well as shingles. Its unlikely to get chicken pox if youve had the chicken pox vaccine.

The best treatment for chicken pox is prevention through vaccination. An early case of chicken pox may be treated with antiviral drugs. Other remedies can be used to ease symptoms.

Read more about chicken pox and how to treat it.

Trending stories,celebrity news and all the best of TODAY.

Also known as fever blisters, cold sores are blisters, or clusters of blisters, that appear on your lips or near your mouth.

Symptoms of cold sores can vary. The sores may start with a tingling, burning or other sensation, then break open and scab over.

Cold sores are caused by the herpes simplex virus. Outbreaks are triggered by stress, fatigue, illness and other factors.

Read more about cold sores and how to treat them.

Almost everyone gets contact dermatitis at some point. There are two main types of contact dermatitis allergic and irritant. Both trigger a rash.

Symptoms of allergic contact dermatitis may include itching, rash, dryness and other symptoms. Cracked, itchy, chapped skin with sores may be signs of irritant contact dermatitis.

Contact dermatitis is caused by something that touches your skin like poison ivy, nickel, fragrances, latex or other irritants and triggers a rash.

The best treatment for contact dermatitis is to avoid whatever it is that triggers your rash. Beyond that, your dermatologist may also recommend antihistamine pills, moisturizers or topical steroids.

Read more about contact dermatitis and how to treat it.

Eczema is a condition that causes red, itchy patches on the skin. It often starts at a young age often people with eczema get it when they're babies.

Eczema is almost always itchy, but otherwise symptoms can vary from person to person. Skin infected with eczema can be dry, dark, scaly, swollen or oozing.

Eczema may be caused by an overactive immune system, but its not entirely clear what causes the condition.

There is no cure for eczema, but symptoms can be managed with medications and other therapies.

Read more about eczema and how to treat it

The onset of hives can be mysterious, and though hives usually go away in less than 24 hours, new ones can repeatedly appear.

Hives appear on the skin as slightly swollen, raised pink or red patches. You may have one hive, a group of hives that may be separate or connected together.

Its difficult to pinpoint the cause of hives, but there are many triggers that can cause hives, from insect bites and allergic reactions to medication, stress and heat.

The go-to treatment for hives is usually antihistamines.

Read more about hives and how to treat them.

People with an allergy to latex are allergic to a protein found in the sap of the Brazilian rubber tree.

Different symptoms appear with different types of latex allergies. One type causes a rash on the skin; another can cause anaphylaxis, which can result in a swelling of the airways and difficulty breathing.

When your immune system reacts as though latex is a harmful substance, it causes an allergic reaction to latex.

Since theres no cure for latex allergies, your best bet is to avoid coming into contact with latex.

Read more about latex allergy and how to treat it.

An autoimmune disease that causes pain and inflammation, lupus can affect your skin, as well as your kidneys, heart, joints and lungs.

A red butterfly-shaped rash that appears on the nose and cheeks is one common sign of lupus, but symptoms of lupus will vary, depending on the type of lupus you have.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about lupus and how to treat it.

Also known as rubeola, measles is a contagious and potentially deadly disease that usually strikes children.

Beyond the signifying red, spotted rash, measles may also be accompanied by a fever, cough, runny nose and other symptoms.

A virus that infects the respiratory tract and spreads throughout the body causes measles. Its one of the most contagious diseases.

The best treatment is prevention through a vaccine. Otherwise, high doses of vitamin A, bed rest and medications to reduce pain and fever may help.

Read more about measles and how to treat it.

Its one of the less common skin cancers, but melanoma is the most dangerous because it can easily spread to other parts of your body.

Melanoma tumors tend to be black or brown, but can sometimes be pink, tan or white. Anyone can get melanoma, but people with light skin are at greater risk.

UV light exposure from ultraviolet rays from the sun or indoor tanning causes most melanomas.

Treatments depend on how advanced the melanoma is and where the tumor is located. It may include surgery, radiation, chemotherapy or other therapies.

Read more about melanoma and how to treat it.

Psoriasis affects more than 8 million people in the U.S. It typically starts in the teen years or early 20s, though it can occur at any age.

When you have psoriasis, your body makes new skin cells quickly, and the cells typically build up in thick, scaly patches on the skin called plaques.

There are a number of factors that may contribute to causing psoriasis. The immune system and genetics may play a role. Certain triggers can also cause the onset of psoriasis and psoriasis flare-ups.

Psoriasis doesnt have a cure, there are medications and treatments that can help manage the condition.

Read more about psoriasis and how to treat it.

This common inflammatory skin condition causes redness of the face.

In addition to causing facial redness, if rosacea is not treated, it can cause visible blood vessels, breakouts like acne and other symptoms.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about rosacea and how to treat it.

Also known as cutaneous squamous cell carcinoma, this cancer develops when the squamous cells in the top layer of your skin grow out of control.

Though its linked with exposure to ultraviolet rays, squamous cell carcinoma can crop up in areas that dont get much sun. Watch out for rough, scaly patches, sores that dont heal or anything else that looks suspicious.

Squamous cell carcinoma is mainly caused by UV rays from the sun or indoor tanning.

Treatments for squamous cell carcinoma may include surgery, radiation or other therapies. Catching it early is key.

Read more about squamous cell carcinoma and how to treat it.

Read the original post:
Skin Disorders: Pictures, symptoms, causes and help - TODAY - TODAY

Recommendation and review posted by Bethany Smith

Image: Steve Wrubel/Parfums Christian Dior By Chloe Pek August 14, 2020

The beauty expert counts Bella Hadid and Kim Kardashian amongst her clientele

Sign up for our newsletters to get all our top stories delivered.

You've Successfully Subscribed

When it comes to facial massages, celebrity facialist Joanna Czech has that magic touch. Counting Hollywood and runway bigwigs like Bella Hadid, Kim Kardashian, Jennifer Aniston, Cate Blanchett, Kate Winslet, Liam Neeson and more amongst her star-studded list of clients, Joannas skincare treatments are highly coveted internationally.

Now, the skincare expert is adding another credential to her portfoliojoining the House of Dior as a skincare ambassador and lending her expertise in developing the Dior skincare techniques international training.

In an interview via Zoom, Czech told us she had her reservations about joining Dior Skincare at first. I mean, theyre famous for make-up and fashion. I couldnt put my name next to fashion skincareIm very particular about that. Then, I heard about how the Capture Totale range stimulates cell energy, so that changed everything and my skin as well.

Czech, who originally planned to go to medical school in her schooling years, fell in love with skincare when she enrolled in the Aesthetics Institute and never looked back. However, she has remained inquisitive and fascinated with science. This is evident from her holistic approach to beauty, which combines both traditional techniques and cutting-edge technology.

See also: The Best Beauty Launches In August 2020

Adenosine triphosphate (ATP, the main carrier of energy for cellular activities) is responsible for the very first mitosis of cells. It is human physiology that production of ATP drastically drops at around seven years old, and the energy keeps slowing down. So any treatment or product that would stimulate cell energy is fascinating to me.

Culminated from Diors decades-long research into stem cells, the Capture Totale line is infused with a regenerative floral complex of Madagascan longozo, Chinese peony, white lily, and Chinese jasmine, which help to re-energise stem cells rather than replenish them.

Dont believe a product that says it contains stem cells because the stem cells are not alive within the product. Only stem cells that are directly re-injectedand most likely come from your bone marrowworks, Joanna explained, debunking one of the most popular beauty fads in recent years.

With the expert on the line, we took the opportunity to ask our burning questions about maskneand skincare misconceptions.

What is a skincare philosophy that you live by?

Respect, support and protect. This goes for skincare, how we treat ourselves and others.

Your all-time favourite Dior Skincare product and why?

The Capture Totale C.E.L.L. Energy Super Potent Serum because it contains the most concentrated version of the cell energising complex and acetylated hyaluronic acid. It creates hydrated, plump and radiant skin. If you are consistent, you see results in days. My skin has never looked better.

A common skincare mistake many people make?

In my opinion, its using toner. Thats a misconception because still, many people use a toner as the second step of cleansing as opposed to the first step of treating the skin, and this is from my experience of talking with clients.

They put toner or micellar water on a cotton pad and they keep wiping and seeing more make-up. If you see more make-up on your cotton pad, that means you need to go back into washing.

Toner is very often misunderstood or skipped, and it shouldnt be. I cant imagine, for instance, applying a serum on my face without applying toner first. There is no way the efficacy of the product will be the same if you have not applied a toner. Depending on the toner, they offer hydration and sometimes micro-exfoliation, but mainly they are used to maintain the pH of the skin. The optimal pH for our skin is 5.5, and many factors from our diet to lifestyle, and even washing our face can throw the skins pH off the scale, so it's very important to balance it back.

See also: Lancme's Celebrity Make-Up Artist Lisa Eldridge & Neelofa Share 5 Beauty Tips

With face masks becoming part of everyday life, maskne has become a real problem. How can we prevent these breakouts?

When you wear a mask, it creates a micro-climate and we keep breathing carbon dioxide back and forth, so there is not enough of anti-bacterial oxygen getting into the skin. There is sometimes too much moisture happening, so we will get super hydrated initially, and then get quite dehydrated right after. Thats when you will experience eczema and redness.

What I recommend is keeping the skin as clean as possible before wearing the mask, with just a balancing toner, and protecting balm or healing ointments to lubricate areas where the mask could potentially irritate the skin. Very often, its on the nose bridge, as well as on the side and behind the ears.

For less reactivity, I wouldnt go through with the whole routine, but if you have to, I would advise starting your routine earlier so the products are on your skin for at least 30-40 minutes. If you will be stepping out shortly, reduce the routine and skip some steps. But no matter what, never forget about your SPF because the friction of the mask could also get rid of our stratum corneum and create little scabs, causing discolourations.

Then, as soon as you arrive home, take the mask off, wash your face, and again balance your skin with toner and use your serums.

What are your tips for soothing breakouts or eczema caused by wearing masks?

Even with microscopic breakouts, I would continue using any product that is hydrating because sometimes we misunderstand we have a breakout and then we try to use benzoyl peroxide, or everything that is dehydrating. No, your skin would be producing even more sebum. So keep hydrating your skin with soothing ingredients like colostrum and hyaluronic acid.

Your skincare routine?

My morning routine is very brief: cleanser, toner, a serum and then there is moisturiser. For my night time routine, my very first step is getting into the shower when I get home. I begin with massaging my body with my shower gel and silicone gloves under the shower, then I apply products like multi-vitamin oils and sometimes micro-exfoliating toners all over my body.

Then, I go to my face. I usually dont wear any make-up, so I start right away with my cleanser with some massaging movements and I remove it with a linen washcloth, followed by a toner. My favourite way of applying toner is the sponge techniqueinitially, you spread the product on your face, and then you press and release. When you press, your skin microscopically opens and when you release, the skin grasps whatever is on the surface.

After the toner, I use my serum. Ive been using the Capture Totale C.E.L.L. Energy Super Potent Serum since September. If you have weaker areas like forehead lines and nasolabial folds, these are the areas I would concentrate longer on, followed by an eye cream and moisturiser. Thats usually my five-step basic routine.

About twice a week, I do facial masks, one of those quick ones because Im the kind of New Yorker who only has five seconds for myself. But no matter how busy or tired I am at night, I would never forget about my skincare routine. Your skin is 60 per cent more potent to absorb everything during relaxation and rejuvenation time. So if you dont take care of your skin at night, you might as well forget doing anything in the morning. Twenty-five per cent of our immune system is within our skin, and we can improve that percentage of our health with products chosen for your skin condition and consistent skincare.

See also: Sulwhasoo's Ginseng To Achieve Skin As Flawless As South Korean Superstar Song Hye Kyo's

You work with many notable clientswhats the most common skincare problem celebrities deal with and treatments that they request for?

Celebrities have exactly the same problems as we do. The only one little difference is that celebrities tend to wear more make-up and more often than some of us, usually under the heat of theatrical or film lights, so they need a lot of hydration and rebalancing. Ive been called to the movie set many times to help soothe their skin with algae masks, or any cooling and hydrating treatments.

Their needs are equal to ours. They want to work on their facial contours and ensure their skin is as evenly textured as possible so their makeup looks perfect, so I would offer some mild exfoliation, perhaps micro-currents for targeted muscle stimulation, and maybe manual massaging to stimulate blood flow to create the sort of rosy healthy oxygenated looking skin. Many people call it a red carpet facial but I call them ordinary facial because every woman wants the samesmooth hydrated skin with nice cheekbones, beautiful jawlines, and thats what really works.

See also: Beauty Talk With Aznita Azman, Founder Of Nita Cosmetics

View original post here:
Dior Skincare Ambassador Joanna Czech On Her Self-Care Routine And How To Prevent Maskne - Tatler Malaysia

Recommendation and review posted by Bethany Smith

The spinal cord is a bundle of nerves inside the spine that gives your body structure and support. Spinal cord injuries (SCIs) tend to be devastating and most are permanent. Recent research has shown that motor neuron obtained from skin cells could serve as potential treatments for spinal cord injuries, and thus has received considerable research attention. With this, a new door has been opened for treating not only spinal cord injuries, caused by workplace accidents and car crashes, but also Lou Gehrigs disease, known as amyotrophic lateral sclerosis or ALS.

A research team, led by Professor Jeong Beom Kim and his research team in the School of Life Sciences at UNIST has demonstrated that human fibroblasts can be converted into induced motor neurons (iMNs) by sequentially inducing two transcription factors, POU5F1(OCT4) and LHX3. The research team further investigated the therapeutic effects of iMNs for treating traumatic spinal cord injury using rodent spinal cord injury model. Their findings indicate that the sequential induction of two transcription factors is essential for generating self-renewing iMNICs more efficiently. This method not only ensures large-scale production of pure iMNs, but also facilitates the feasibility of iMNs for SCI treatment.

The spinal cord is responsible for transmitting signals from the brain to the rest of the body, and vice versa. Along with motor and sensory deficits, damage to the spinal cord can cause long-term complications, including limited mobility. Although there are many treatment options available for people with SCI, most of them have adverse side effects that impact therapy. And this is why stem cell (SC) therapies to restore functions of damaged tissues are attracting attention, recently. Among those cells constituting the spinal cord, motor neurons that involved in the regulation of muscle function have emerged as a promising candidate for the stem cell-based therapy for SCIs. Despite these encouraging advances, ethical issue of embryonic stem cells (ESCs) and tumorigenic potential of induced pluripotent stem cells (iPSCs) have impeded their translations into clinical trials.

Figure 1. The experimental scheme for the generation of induced motor neurons (iMNs) from human fibroblasts via sequential transduction of two transcription factors.

To overcome these limitations, Professor Kim and his research team established an advanced direct conversion strategy to generate iMNs from human fibroblasts in large-scale with high purity, thereby providing a cell source for the treatment of SCI. These iMNs possessed spinal cord motor neuronal identity and exhibit hallmarks of spinal MNs, such as neuromuscular junction formation capacity and electrophysiological properties in vitro. Importantly, their findings also show that transplantation of iMNs improved locomotor function in rodent SCI model without tumor formation. According to the research team, This proof-of-concept study shows that our functional iMNs can be employed to cell-based therapy as an autologous cell source. Through this, they resolved the problem of immune rejection, and thus reduce the risk of cancer.

In the study, we succeeded in generating iMNs from human fibroblasts by overexpressing POU5F1(OCT4) and LHX3, says Hyunah Lee (Combined MS/Ph.D program of Life Sciences, UNIST), the first author of the study.

Figure 2. Therapeutic effects of iMNs in rat spinal cord injury model in vivo. (A) The position of hindlimbs in control rat and iMN-transplanted rat after 8 weeks of transplantation. (B) C staining analysis of spinal cords after 8 weeks of transplantation (I; Control, J; iMN-transplanted).

The developed motor nerve cell manufacturing method has the advantage of being capable of mass production. A sufficient amount of cells is required for patient clinical treatment, but the existing direct differentiation technique has limited the number of cells that can be obtained. On the other hand, the method developed by the research team is capable of mass production because it undergoes an intermediate cell stage capable of self-renewal. After injecting the produced cells into the spinal cord injury mice, it was confirmed that the lost motor function is restored and the nerves are regenerated in the damaged spinal cord tissue.

Although further investigation on mechanism responsible for cell fate conversion may be needed, our strategy is a safer and simpler methodology that may provide new insights to develop personalized stem cell therapy and drug screening for MN diseases or spinal cord disorders, says Professor Kim. If combined with SuPine Patch, an adhesive hydrogel patches with the purpose of regenerating the damaged spinal cords, its therapeutic effects will be maximized. He adds, As the incidence of spinal cord injury is high due to industrial accidents, synergistic effects with public hospitals specializing in industrial accidents scheduled to be built in Ulsan should be expected.

This study has been jointly carried out with Professor Kims startup company, SuPine Therapeutics Inc. with the support of the Ministry of SMEs and Startups (MSS). The findings of this research have been published in the 2020 June issue of the online edition of eLife, a renowned academic journal of the European Molecular Biology Organizationl (EMBO).

Journal Reference

Hyunah Lee, Hye Yeong Lee, Byeong Eun Lee, et al., Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model, eLife, (2020).

Read more:
New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders - Mirage News

Recommendation and review posted by Bethany Smith

What is testicular cancer?

Testicular cancer arises from the testes (a part of the male reproductive system). The testicles are responsible for the production of male sex hormones and sperm for reproduction. They are located within the scrotum, a loose bag of skin below the penis. Testicular cancer is the most common type of cancer occurring in males in the US between the ages of 15 and 35.

Testicular cancer can be aggressive and grow and spread rapidly. However, this cancer is highly treatable even after it spreads. Hence, the prognosis for men with testicular cancer is good. Studies have shown that the risk of dying from testicular cancer is about1 in 5,000.

How is testicular cancer treated?

The treatment may involve one or a combination of multiple treatment modalities, which depends on the extent of the disease.

The treatment options include

What causes testicular cancer?

The exact cause of testicular cancer is unknown. Some factors increase the risk of testicular cancer, including

What are the warning signs of testicular cancer?

The initial signs and symptoms of testicular cancer include

What are the types of testicular cancer?

Most testicular cancers are germ cell (cells that produce sperm) tumors. There are two main types of testicular cancer, seminomas and nonseminomas.

How is testicular cancer diagnosed?

Medically Reviewed on 8/13/2020

References

Medscape

American Cancer Society

Medline

Continued here:
What Are the Five Warning Signs of Testicular Cancer? - MedicineNet

Recommendation and review posted by Bethany Smith

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Stem Cell-Derived Cells market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Stem Cell-Derived Cells market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Stem Cell-Derived Cells market to assist our clients arrive at beneficial business decisions.

The Stem Cell-Derived Cells market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Stem Cell-Derived Cells market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

What pointers are covered in the Stem Cell-Derived Cells market research study?

The Stem Cell-Derived Cells market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Stem Cell-Derived Cells market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Stem Cell-Derived Cells market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28780

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Stem Cell-Derived Cells market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Stem Cell-Derived Cells market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Stem Cell-Derived Cells market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

Some of the Major Highlights of TOC covers:

See more here:
Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Owned

Recommendation and review posted by Bethany Smith

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Dry AMD is a leading cause of permanent vision loss in people over the age of 50. GT005 is a one-time AAV-based gene therapy that is delivered under the retina. The goal of the Phase II clinical trial programme is to determine if GT005 has the potential to slow the progression of GA.

Gyroscope plans to conduct two Phase II trials evaluating GT005 in people with GA. The first, called EXPLORE, is enrolling people who have a mutation in their Complement Factor I (CFI) gene [NCT04437368]. The first patient to receive GT005 in EXPLORE was enrolled and dosed by Dr. Arshad M. Khanani at Sierra Eye Associates in Reno, Nev., USA.

Geographic atrophy is a devastating diagnosis, as there are no approved treatments for this gradual and irreversible loss of vision, said Arshad M. Khanani, M.D., M.A., Director of Clinical Research at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine, and an investigator in the EXPLORE trial. We are excited to participate in this trial evaluating GT005 for the potential to slow progression of geographic atrophy. We believe one-time gene therapies could be a major advancement in the field of retinal disease.

GT005 is designed to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. An overactive complement system has been implicated in the development of AMD. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production will dampen the systems overactivity and reduce inflammation, with the goal of preserving a persons eyesight.

Research has found that approximately 3% of people with dry AMD have certain CFI mutations that correlate with low CFI levels in the blood and a higher risk of developing AMD.1 Gyroscope estimates that more than 100,000 people with GA in the United States and EU5 European countries may have these mutations.1,2,3,4 The EXPLORE trial will evaluate GT005 in this group of people with mutations in their CFI gene.

Research has also shown that a small supplementation of CFI can normalise complement activity in the blood,5 suggesting GT005 may also be applicable for a broader group of people with GA. It is estimated that approximately one million people in the United States alone have GA.4 Gyroscope therefore plans to initiate a second Phase II trial in 2020 that will evaluate GT005 in a broader GA population.

We are excited about the potential of GT005 for people with dry AMD. Research suggests GT005 may be best suited for people with certain mutations in their CFI gene. However, evidence also suggests it may have potential for a broader population of people with geographic atrophy, said Nadia Waheed, M.D., MPH, Chief Medical Officer of Gyroscope. We have designed our clinical programme to evaluate these groups in two distinct Phase II trials, with the goal of determining which patients GT005 may be most appropriate for and to further our understanding of the role of the complement system in AMD.

About the EXPLORE Trial

EXPLORE is a Phase II, multicentre, randomised trial evaluating the safety and efficacy of GT005 administered as a single subretinal injection.

EXPLORE is enrolling people who are aged 55 or older and have a clinical diagnosis of GA secondary to dry AMD and who have a mutation of the CFI gene. People being screened for the trial will be genotyped for the mutations. Trial participants will be randomised to one of three treatment arms: GT005 dose 1, GT005 dose 2 or a control arm. Participants in the control arm will receive current standard of care. The primary endpoint of EXPLORE is progression of GA over 48 weeks. The study will also evaluate GT005 for various safety and tolerability measures. Gyroscope plans to enroll approximately 75 patients at approximately 40 centres based in the United States, United Kingdom, Europe and Australia.

Gyroscope will announce details about the second Phase II trial of GT005 at a later date.

About Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA)

AMD is a leading cause of blindness affecting an estimated 196 million people globally.6 AMD typically affects people aged 50 and older, and causes a gradual and permanent loss of central vision that worsens over time.7 There are no approved treatments for the dry form of AMD, which is the most common, impacting approximately 90% of people with the disease.8 As dry AMD advances it leads to GA, an irreversible degeneration of retinal cells. This vision loss can be devastating, severely impacting a persons daily life as they lose the ability to drive, read and even see the faces of loved ones.

About Gyroscope Therapeutics: Vision for Life

Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing and delivering gene therapy beyond rare disease to treat a leading cause of blindness, dry AMD. Our lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and a Phase II clinical trial called EXPLORE.

Syncona Ltd, our lead investor, helped us create the only retinal gene therapy company to combine discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. For more information visit: http://www.gyroscopetx.com and follow us on Twitter (@GyroscopeTx) and on LinkedIn.

References

1 Kavanagh D, Yu Y, Schramm EC, et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet. 2015;24(13):3861-3870.

2 Data on File.

3 Friedman DS, OColmain BJ, Muoz B, et al. Prevalence of age-related macular degeneration in the United States [published correction appears in Arch Ophthalmol. 2011 Sep;129(9):1188]. Arch Ophthalmol. 2004;122(4):564-572.

4 Rudnicka AR, Kapetanakis VV et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol 2015;160:85-93.

5 Lachmann PJ, Lay E, Seilly DJ, Buchberger A, Schwaeble W, Khadake J. Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype. Clin Exp Immunol. 2016;183(1):150-156.

6 Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106116.

7 National Eye Institute. Age-Related Macular Degeneration. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration. Accessed July 16, 2020.

8 Centers for Disease Control and Prevention. Age-Related Macular Degeneration. https://www.cdc.gov/visionhealth/basics/ced/. Page last reviewed June 3, 2020. Accessed August 4, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005751/en/

Charlotte Arnold

VP, Corporate Affairs

Gyroscope Therapeutics

media@gyroscopetx.com

Follow this link:
Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular...

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

With this research service, the publisher's Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments - antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market until 2024 reveals an interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.

This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market.

Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed.

Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of speciality bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, the group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.

Research Highlights

Highlights of the report include:

Key Issues Addressed

Key Topics Covered:

1. Executive Dashboard

2. Market Overview - Biologics

3. Market Dynamics

4. COVID-19 Impact Analysis of the Biologics Market

5. Revenue Forecast - Total Biologics Market

6. Antibody Therapies Segment Analysis

7. Recombinant Proteins Segment Analysis

8. Vaccines Segment Analysis

9. Cell & Gene Therapy Segment Analysis

10. Companies to Action - Pipeline Analysis

11. Growth Opportunities

12. The Last Word

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/g4tkkr

Excerpt from:
Global Biologics Market and Curative Oncology and Rare Disease Therapies to 2024 - COVID-19 Impact Analysis - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

The Gene Therapy market report covers the overview of the market and presents the information on business development, market size, and share scenario. The report also emphasizes on the growth prospects of the global Gene Therapy market for the period 2020-2025. The report covers market characteristics for each segmentation across the key regions and country and traces the historic and forecast analysis of the industry. The report covers key vendors their revenue, breakdown by regions, and product demand. Other key details include volume, installed capacity and value chain.

Executive Summary:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/35520

The research report on Gene Therapy market delivers vital data regarding this industry landscape while elaborating on the major growth drivers, limitations & challenges, opportunities, and future prospects impacting the business outlook.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/35520

According to the study, the Gene Therapy market is expected to register a CAGR of XX% during the study period.

Crucial insights pertaining to the regional scope, competitive scenario and other factors influencing the growth pattern of each market segment are encompassed in the document. In addition, the report gauges the impact of COVID-19 outbreak on the revenue graph of this market.

Market Rundown:

Regional Analysis:

Product terrain outline:

Application range overview:

Competitive arena review:

Here are the questions we answer

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/35520

Follow this link:
Gene Therapy Market Applications, Types and Future Outlook Report 2020-2025 - CueReport

Recommendation and review posted by Bethany Smith

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.

AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem), for ImStem to utilize AgeXs ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.

We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology, said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.

AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.

AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far, said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.

Q2 Highlights

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.

Staff Reductions

In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Second Quarter 2020 Operating Results

Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

June 30,2020

December 31,2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,033

$

2,352

Accounts and grants receivable, net

235

363

Prepaid expenses and other current assets

836

1,339

Total current assets

2,104

4,054

See the original post here:
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire

Recommendation and review posted by Bethany Smith

NEW YORK, Aug. 12, 2020 /PRNewswire/ --

INTRODUCTION Since the approval and launch of cell and gene therapy products, such as Zolgensma (2019), ZYNTEGLO (2019), Luxturna (2017), KYMRIAH (2017) and YESCARTA (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019. Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings. Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.

Read the full report: https://www.reportlinker.com/p05950929/?utm_source=PRN

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging. Existing separation and purification techniques are not efficient when it comes to purifying viral vectors at large scales. Moreover, these techniques are often unable to separate complete viruses from empty capsids, thereby, compromising product recovery. Therefore, it has become essential for stakeholders to develop innovative ways to optimize the purification process, in order to further improve virus recovery and facilitate effective removal of contaminants / impurities. Currently, the viral vector purification products market is driven by abovementioned surge in demand for viral vectors. In this context, it is worth mentioning that there are several virus based vaccines under development against the novel SARS-CoV-2 coronavirus strain. In fact, according to the WHO, there are over 20 viral vaccines currently being investigated against the novel coronavirus. Developing the means to better purify viruses is, therefore, likely to significantly impact viable vaccine yield. The current crisis is definitely going to have a strong impact on the virus purification products market.

SCOPE OF THE REPORT The 'Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030' report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features: - An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time). In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters. - Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook. - An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector, developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline. - A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, geographical location, number of patients enrolled and key players. - An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location. - A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area. - A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] key geographical regions (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals: - Haifeng Chen (Chief Executive Officer, Virovek) - Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) - Kai Lipinski (Chief Scientific Officer, Vibalogics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include - Annual reports - Investor presentations - SEC filings - Industry databases - News releases from company websites - Government policy documents - Industry analysts' views While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the viral vector purification product in the short to mid-term, and long term.

Chapter 3 provides a general overview of various types of viral and non-viral vectors. It includes a detailed discussion on the methods of gene transfer, type of viral vectors and applications of viral vectors in various advanced therapies. It provides information on the different stages of the viral vector purification process, type of purification techniques used and the key challenges associated with the purification of viral vectors. Further, it includes a review of the latest trends and innovations in the vector purification market.

Chapter 4 is an overview of the various types of products used for purification techniques based on principles of chromatography, centrifugation and filtration. It highlights product specific information, such as type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (adenovirus, AAV, lentivirus, retrovirus and others), type of chromatographic technique (affinity chromatography, ion-exchange chromatography, size-exclusion chromatography and hydrophilic interaction chromatography), pack size (wherever specified) and price (wherever specified). In addition, the chapter provides details on certain additional parameters (based on the purification technique, wherever applicable), such as type of matrix, binding capacity, particle size, volume of bed, flow rate, operating pressure, working temperature, process time and pH. The chapter also provides information on the purification product developers, including year of establishment, company size and location of headquarters.

Chapter 5 includes detailed profiles of players offering products for viral vector purification. Each profile features an overview of the company, , information on its product portfolio, recent developments and an informed future outlook. Chapter 6 highlights potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on multiple parameters, such as type of viral vector, developer strength, operational strength, therapeutic areas, strength of clinical pipeline and strength of preclinical pipeline. The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.

Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of viral vector-based cell therapies, gene therapies and vaccines (approved / under development). The analysis provides details related to the different types of viral vectors investigated / being investigated across various geographies, based on the number of clinical trials, registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, number of patients enrolled, key players and type of viral vector.

Chapter 8 features an informed estimate of the annual demand for viral vectors, taking into account the viral vector based marketed therapies and clinical studies. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength. The chapter features analyses demand on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.

Chapter 9 is a detailed case study which provides an overview of the tangential flow filtration, highlighting its role, advantages and disadvantages. It features key details of the products used for tangential flow filtration, such as type of product, scale of operation, membrane material, flow rate and filtration area.

Chapter 10 is a detailed case study which provides an overview of the viral vector manufacturers. It features an in-depth analysis of the commercial scale viral vector manufacturers, highlighting details on their year of establishment, company size, types of vectors (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), headquarters and manufacturing facilities.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the virus purification products market till the year 2030. We have segregated the opportunity of the market on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] geographical location (North America, Europe, Asia Pacific and rest of the world).

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order) Haifeng Chen (Chief Executive Officer, Virovek), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) and Kai Lipinski (Chief Scientific Officer, Vibalogics).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in this report.

Read the full report: https://www.reportlinker.com/p05950929/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Link:
Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent, and others),...

Recommendation and review posted by Bethany Smith

The persuasive Gene Therapy Products Market research report provides explanation about market trends, future prospects, market restraints, leading market drivers, market segments, key developments, key players in the market, and competitor strategies. A thorough analysis has been performed in this report to know the potential of the market in the present and the future prospects from various angles. This Gene Therapy Products Market document also contains a precise investment analysis which forecasts forthcoming opportunities for the market players in the Healthcare industry. Gene Therapy Products Market research analysis is one of the finest options to resolve business challenges quickly by saving lot of time.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-gene-therapy-products-market

Global gene therapy products market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cancer cases and unused potential for emerging markets are the major factors for the growth of this market.

Few of the major competitors currently working in the globalgene therapy products marketareAdaptimmune., Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION, GlaxoSmithKline plc., Merck KGaA, Novartis AG, Achieve Life Sciences, Inc., Spark Therapeutics, Inc., Abeona Therapeutics, Inc, Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis, Inc., CRISPR Therapeutics, Intellia Therapeutics, Inc and Gilead Sciences,Inc. among others.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-gene-therapy-products-market

Market Definition:Global Gene Therapy Products Market

Gene therapy or human gene therapy is a process which is used to modify gene for the treatment of any disease. Plasmid DNA, bacterial vector, human gene editing technology and viral vectors are some of the most common type of gene therapy products. The main aim of the gene therapy is to replace the dysfunctional genes. Somatic and germline are some of the most common type of the gene therapy.

Segmentation: Global Gene Therapy Products Market

Gene Therapy Products Market : By Product

Gene Therapy Products Market : By Application

Gene Therapy Products Market : ByGeography

Key Developments in the Gene Therapy Products Market:

Gene Therapy Products Market Drivers

Gene Therapy Products Market Restraints

Key questions answered in the report :

To get this report at an attractive cost, click herehttps://www.databridgemarketresearch.com/speak-to-analyst?dbmr=global-gene-therapy-products-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Continue reading here:
Gene Therapy Products Market is Slated To Witness Tremendous Growth in Coming Years | Major Players GlaxoSmithKline plc., Merck KGaA, Novartis AG,...

Recommendation and review posted by Bethany Smith

The report is an all-inclusive research study of the global Cancer Gene Therapy market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Cancer Gene Therapy market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Cancer Gene Therapy report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

The Cancer Gene Therapy Market carries out financial changes that occur year by years in market, with information about upcoming opportunities and risk to keeps you ahead of competitors. The report also describes top company profiles that present in market with trends worldwide. This research guided you for extending business.

The Cancer Gene Therapy Market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, and product type and distribution channels.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2081748&source=atm

The key players covered in this studyAdaptimmuneBluebird bioCelgeneShanghai Sunway BiotechShenzhen SiBiono GeneTechSynerGene TherapeuticsAltor BioScienceAmgenArgenxBioCancellGlaxoSmithKlineMerckOncoGenex PharmaceuticalsTransgene

Market segment by Type, the product can be split intoOncolytic VirotherapyGene TransferGene-Induced Immunotherapy

Market segment by Application, split intoHospitalsDiagnostics CentersResearch Institutes

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

A proper understanding of the Cancer Gene Therapy Market dynamics and their inter-relations helps in gauging the performance of the industry. The growth and revenue patterns can be revised and new strategic decisions taken by companies to avoid obstacles and roadblocks. It could also help in changing the patterns using which the market will generate revenues. The analysis includes an assessment of the production chain, supply chain, end user preferences, associated industries, proper availability of resources, and other indexes to help boost revenues.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2081748&source=atm

Market Segmentation based On Type, Application and Region:

The global Cancer Gene Therapy is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application and Region.

Global Cancer Gene Therapy market is presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the global market.

The Global Cancer Gene Therapy Market is gaining pace and businesses have started understanding the benefits of analytics in the present day highly dynamic business environment. The market has witnessed several important developments over the past few years, with mounting volumes of business data and the shift from traditional data analysis platforms to self-service business analytics being some of the most prominent ones.

For the future period, sound forecasts on market value and volume are offered for each type and application. In the same period, the report also provides a detailed analysis of market value and consumption for each region. These insights are helpful in devising strategies for the future and take necessary steps. New project investment feasibility analysis and SWOT analysis are offered along with insights on industry barriers. Research findings and conclusions are mentioned at the end.

Reasons for Buying This Report:

It Provides A Forward-Looking Perspective on Different Factors Driving or Restraining Market Growth.

It Provides A Five-Year Forecast Assessed on The Basis of How the Market Is Predicted to Grow

It Helps in Understanding the Key Product Segments and Their Future.

It Provides Pin Point Analysis of Changing Competition Dynamics and Keeps You Ahead of Competitors.

It Helps in Making Informed Business Decisions by Having Complete Insights of Market and By Making an In-Depth Analysis of Market Segments.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2081748&licType=S&source=atm

Table of Content:

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Cancer Gene Therapy Market to Enable the Stakeholders to Capitalize on the Prevailing Industry Opportunities with Investment Analysis By Top Players -...

Recommendation and review posted by Bethany Smith

With this research service, our Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth.

New York, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 20202024" - https://www.reportlinker.com/p05950884/?utm_source=GNW The global biologics market covered in this study includes 4 major segments antibody therapies, recombinant proteins, vaccines, and regenerative medicine.

The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, our group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.Read the full report: https://www.reportlinker.com/p05950884/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the rest here:
Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 20202024 - Yahoo Finance

Recommendation and review posted by Bethany Smith

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.

This study, now set to begin recruiting patients in Brazil, follows the same protocol approved by the US Food and Drug Administration in April a multicenter, randomized, placebo-controlled, double-blinded clinical trial focused on hospitalized severe and critical adult COVID-19 patients at high risk of disease progression. Humanigen is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.

Cameron Durrant, MD, MBA, chief executive officer of Humanigen, said, COVID-19 is a global crisis and we are committed to offering assistance to patients across the world that are impacted by the pandemic. We hope that expanding the study of lenzilumab to research centers in Brazil, a country with surging rates of COVID-19, will offer patients much needed access to a leading COVID-19 therapeutic candidate.

Currently, Brazil has the second highest reported rates of COVID-19 infection in the world, second only to the US.

Access to clinical trials is critical for healthcare providers in the fight against COVID-19, remarked Timothy Schroeder, chief executive officer of CTI. We are proud to collaborate with our colleagues at Humanigen to extend the reach of the Phase III study of lenzilumab and bring a potential treatment option to those in need.

More details on Humanigens programs in COVID-19 can be found on the companys website at http://www.humanigen.com under the COVID-19 tab, and details of the US Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO) recently named #1 CRO in the world for quality, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit http://www.ctifacts.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations surrounding our ongoing and anticipated clinical trial activities in the United States and Brazil and our operational, research, development or commercialization activities for lenzilumab and the other product candidates in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

See the original post here:
Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil - Business Wire

Recommendation and review posted by Bethany Smith

Most patients with Hodgkin lymphoma (HL), a type of cancer of immune cells called B lymphocytes, are cured with first-line therapy, but approximately 15 percent have primary refractory disease or relapse after an initial response to treatment.

Dr. Carlos Ramos at Baylor College of Medicine and his colleagues at Baylor and the University of North Carolina Lineberger Comprehensive Cancer Center have tackled relapsing or refractory HL with a novel treatment combination that produced promising results in a clinical trial.

In a 2017 pilot study in seven refractory/relapsing Hodgkin lymphoma patients, Baylor and UNC researchers found that a CAR-T cell therapy targeting Hodgkin cell-associated protein CD30 appeared safe but brought about only modest responses, said Ramos, co-first author of the study and professor in the Margaret M. and Albert B. Alkek Department of Medicine and the Center for Cell and Gene Therapy at Baylor, Houston Methodist Hospital and Texas Childrens Hospital.

In the new study, which included 41 patients treated at Baylor and UNC, the researchers used the same anti-CD30 CAR-T cell strategy, but added a preparative regimen in which patients existing lymphocytes a broad family of white blood cells including T cells were greatly depleted with chemotherapy drugs prior to the addition of the CAR-T cells.

The combination of lymphodepletion with anti-CD30 CAR-T led to the complete disappearance of tumor in the majority of patients treated at the highest dose level of therapy, with almost all patients having clinical benefit after treatment, said Ramos, a member of the Dan L Duncan Comprehensive Cancer Center at Baylor.

Lymphodepletion prior to CAR-T cell infusion seems to produce a more favorable environment for the CAR-T cells to proliferate and attack their cancerous targets, said Dr. Natalie Grover, study co-first author, assistant professor in the UNC Department of Medicine and a UNC Lineberger member.

These results are particularly exciting because the majority of these patients had lymphomas that had not responded well to other powerful new therapies, said study senior author Dr. Barbara Savoldo, professor in the UNC Department of Microbiology and Immunology at the UNC School of Medicine and a UNC Lineberger member. Everyone worked tirelessly on the study, and I am proud of the collaborative work it fueled between UNC Lineberger and Baylor.

I am very pleased to see this strategy, developed by Dr. Savoldo when she was at Baylor and initially translated to the clinic with Dr. Ramos, has now been validated in larger clinical trials at two centers, said co-author Dr. Helen Heslop, director of the Center for Cell and Gene Therapy and a Dan L Duncan Chair at Baylor.

Side effects of the lymphodepletion plus CAR-T cell treatment were common and included flu-like symptoms due to an immune chemical storm called cytokine release syndrome, but these events were generally modest. None of the patients experienced the more serious, life-threatening complications, such as brain swelling, that have been seen in CAR-T cell trials against other blood cancers.

As the trial progressed, the researchers settled on fludarabine as a key element of the pre-therapy lymphodepletion regimen, since patient outcomes seemed better when it was used. The researchers found that among the 32 patients with active cancer who received fludarabine for lymphodepletion before their CAR-T cells, 19 patients (59 percent) had a complete response.

Of the patients in the study who had a complete response, 61 percent still had no evidence of recurrence a year later. Overall, 94 percent of the treated patients were still alive a year after their treatment.

One patients remarkable recovery is detailed in the Dan L Duncan Comprehensive Cancer Center Annual Report. The researchers hope to do further studies of the CAR-T cell therapy alone and in combination with other new immune-modulating anticancer drugs.

Read the complete study in the Journal of Clinical Oncology

Other authors who contributed to this work include Dr. Anne W. Beaven, Dr. Premal D. Lulla, Meng-Fen Wu, Dr. Anastasia Ivanova, Dr. Tao Wang, Dr. Thomas C. Shea, Dr. Cliona M. Rooney, Christopher Dittus, Steven I. Park, Dr. Adrian P. Gee, Dr. Paul W. Eldridge, Kathryn L. McKay, Birju Mehta, Catherine J. Cheng, Faith B. Buchanan, Bambi J. Grilley, Dr. Kaitlin Morrison, Dr. Malcolm K. Brenner, Dr. Jonathan S. Serody and Dr. Gianpietro Dotti. The authors are affiliated with Baylor College of Medicine and the University of North Carolina at Chapel Hill.

The research was supported by the National Institutes of Health (RO1HL114564, P50CA126752, P30 CA125123, K12CA120780), the University Cancer Research Fund, and the Leukemia Lymphoma Society.

By Molly Chiu

Read more here:
CAR T cell therapy makes strides in tackling Hodgkin lymphoma - Baylor College of Medicine News

Recommendation and review posted by Bethany Smith

Global Cancer Gene Therapy Market Size, Share, Growth Trends, Industry Report from DBMR highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, players market shares, and strategies that are key in the market. Cancer Gene Therapy Market research report provides key analysis on the market status of the Cancer Gene Therapy manufacturers with market size, growth, share, demand, revenue, trends as well as industry cost structure. The exploration provides a 360 view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions.

According to DBMR, the GlobalCancer Gene Therapy Marketis expected to see a growth rate of 32.54%. The high success rate of cancer gene therapy along with clinical trial and the preclinical trial is gaining popularity among the patient which is leading towards the market.

Download Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-gene-therapy-market

Market Overview of Global Cancer Gene Therapy

Increase in funding of research and development in the activities of cancer gene therapy along with rise in prevalence of cancer is likely to accelerate the growth of the cancer gene therapy market in the forecast period of 2020-2027. On the other hand, the favourable government regulations for therapy is further going to boost various opportunities that will lead to the growth of the cancer gene therapy market in the above mentioned forecast period. High cost involved in gene therapy along with unwanted immune responses wills likely to hamper the growth of the cancer gene therapy market in the above mentioned forecast period.

Global Cancer Gene Therapy Market Research Report also provides the latest companies data and industry future trends, allowing you to identify the products and end users driving profits growth and productivity. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, investigation and discussion of significant industry trends, market volume, market share estimates and profiles of the leading industry Players. Global Cancer Gene Therapy Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details.

To Get the Short-Term and Long-Term Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-covid-19/global-cancer-gene-therapy-market

The titled segments and sub-section of the market are illuminated below

By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer)

By End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories)

Top Key Manufactures or Players (this may not be a complete list and extra companies can be added upon request):

Adaptimmune

GlaxoSmithKline plc

bluebird bio, Inc

Merck & Co., Inc

CELGENE CORPORATION

Anchiano Therapeutics

Achieve Life Sciences

..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-gene-therapy-market

The report also focuses on global major leading industry players of Global Cancer Gene Therapy Market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Global Cancer Gene Therapy market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Cancer Gene Therapy Market Scope and Market Size

Cancer gene therapy market is segmented on the basis of therapy and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on therapy, the cancer gene therapy market is segmented into oncolytic virotherapy, gene induced immunotherapy and gene transfer. The oncolytic virotherapy is further sub-segmented into adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus and others. The gene induced immunotherapy is further sub-segmented into delivery of cytokines gene and delivery of tumor antigen gene. The gene transfer is further sub-segmented into naked/plasmid vectors, electroporation, sonoporation, magnetofection and gene gun.

Cancer gene therapy market has also been segmented based on the end user into hospitals, oncology institutes, biotechnological companies and clinical research laboratories.

According to the Regional Segmentation the Cancer Gene Therapy Market provides the Information covers following regions:

North America

South America

Asia & Pacific

Europe

MEA (Middle East and Africa)

The key countries in each region are taken into consideration as well, such as United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

North America dominates the cancer gene therapy market due to the advanced healthcare infrastructure along with rise in R & D expenditure, while Asia-Pacific is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 due to the improving healthcare infrastructure and government initiatives.

For More Information or Query or Customization Before Buying,[emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-gene-therapy-market

Scope of Report:

The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the Cancer Gene Therapy market. The Global Cancer Gene Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

Important Features that are under offering & key highlights of the report:

Market Data Segmentation with production, consumption, revenue (million USD), and Price Analysis

Detailed overview of Cancer Gene Therapy market

Changing market dynamics of the industry and Impact of Influencing Factors

In-depth market segmentation by Type, Application and other major segments etc.

To analyse and forecast the Global Cancer Gene Therapy market, in terms of value and volume.

Which segment has the potential to gain the highest market share?

To help decision maker from new offer perspective and benchmark existing marketing strategy.

Correlate cost structure historical data with key business segments.

Analyse marketing contribution and customer acquisition by up-selling and cross selling.

Identifying Influencing factors keeping Global Cancer Gene Therapy Market Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Order a Copy of Cancer Gene Therapy Market[emailprotected]https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cancer-gene-therapy-market

With tables and figures helping analyze worldwide Global Cancer Gene Therapy market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Major Highlights of TOC:

Chapter One: Market Overview

1.1. Introduction

1.2. Scope/Objective of the Study

Chapter Two: Executive Summary

2.1. Introduction

Chapter Three: Market Dynamics

3.1. Introduction

3.2. Market Drivers, Trends, Challenges, Opportunities

Chapter Four: Market Factor Analysis

4.1. Porters Five Forces

4.2. Supply/Value Chain

4.3. PESTEL analysis

4.4. Market Entropy

4.5. Impact Analysis Post COVID-19

Continued !!!

Chapter Nine: Methodology and Data Source

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Our Other Reports:

Remote Patient Monitoring and Care Market 2020 Size, Growth, Trends, Industry Share, Emerging Technologies &Top Players by Abbott, Baxter, Boston Scientific, Medtronic, Omron Healthcare, BioTelemetry

Legal Marijuana Market Size, Growth Analysis 2020, Industry Statistics, Value, Demand, Future Trends, Top Leaders-VIVO Cannabis, Dr. Hemp Me, QC Infusion, Green Roads, Royal CBD, CBD Oil Europe, King CBD

CBD Oil Industry 2020-Market Size, Share, Demand, Growth, Global Top Companies-Canazil, Kazmira, Spring Creek Labs, Isodiol International, HempLife Today, Hemp Oil Canada, Medical Marijuana

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read more:
Cancer Gene Therapy Market Predicted to Witness Sustainable Evolution in Years to : Industry Outlook: Post COVID Investors Eye Bigger-Than-Expected...

Recommendation and review posted by Bethany Smith

What You Should Know:

Mission Bio raises $70 million in Series C funding led byNovo Growth to accelerate the development of cancer therapies with single-cell multi-omics.

Mission Bios Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to accelerate the development of novel treatments and save patient lives.

Mission Bio,Inc., a South San Francisco, CA-based pioneer in high-throughputsingle-cell DNA and multi-omic analysis, today announced $70 million in itsSeries C financing led by Novo Growth. Soleus Capital also joins the round, alongwith earlier investors Mayfield, Cota, and Agilent, bringing the companys totalfunding to more than $110 million.

Lack of Understanding at the Single-Cell Level

Cancer is a disease of single cells, and it is driven by DNAmutations. Until now, weve been using outdated tech thats misled us to focuson the wrong parts of these cancer cells. Due to this, our currentunderstanding of the disease at the single-cell level has been incomplete.

Only 3% of cancer drugs tested in clinical trials between2000 and 2015 have been approved to treat patients, and even those that havebeen approved are not as effective as wed hope. Even those aimed at specificbiomarkers like DNA mutations arent effective in every patient with thatmutation, resulting in high rates of relapse. Ultimately, the complexity ofdisease evolution and therapy response requires comprehensive tools tocharacterize how DNA mutations drive disease at the cellular level, includingfunctional changes in the protein. To develop durable therapies, we require adeeper understanding of all analytes of the cell.

One Platform. Genotype + Phenotype

Founded in 2014, Mission Bio Is the first and onlysingle-cell multi-omics platform developed to accelerate the discovery,development, and delivery of treatments for cancer. The Tapestri Platform isthe first-ever single-cell multi-omics platform capable of detecting DNA andprotein changes simultaneously from the same cell a capability necessary forthe development of impactful precision therapies.

The award-winning technology has been adopted by Agios, LabCorp, Onconova Therapeutics, andother companies to optimize clinical trials and improve the likelihood ofsuccess. Leading cancer centers, including Stanford, MD Anderson Cancer Center,the University of California at San Francisco, and Memorial Sloan KetteringCancer Center, have leveraged the Tapestri Platform to support their work intherapeutic resistance and treatment response monitoring.

Over the past year, Mission Bio has advanced its efforts tosupport drug development through clinical trials and the translation ofresearch into novel biomarkers with its growing install base in NCI cancercenters and key biopharma companies.

Expansion Plans

To support Mission Bios rapid growth, the funds will scaleits single-cell multi-omics technology, the Tapestri Platform, to expand thecompanys reach in more effective clinical trials for novel cancer treatments,along with expanding in cell and gene therapy.

Were on a mission to help our customers eliminate cancer. With access to multiple layers of the cellular profile, the Tapestri Platform can help identify novel biomarkers in diseased cells, monitor therapy resistance and response, and accelerate novel therapies through clinical trials, said Charlie Silver, CEO, and Founder of Mission Bio. We are delighted to partner with Novo Growth to advance our impact in drug development and cell and gene therapy.

See more here:
Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform - HIT Consultant

Recommendation and review posted by Bethany Smith